SYSTEMATIC REVIEW

Open Access

Comparing the efficacy of unilateral biportal endoscopic transforaminal lumbar interbody fusion and minimally invasive transforaminal lumbar interbody fusion in lumbar degenerative diseases: a systematic review and meta-analysis

Haopeng Luan^{1†}, Cong Peng^{1†}, Kai Liu² and Xinghua Song^{1*}

Abstract

Objective To compare the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion (BE-TLIF) and minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in lumbar degenerative diseases.

Methods This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42023432460). We searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wan Fang Database, and Wei Pu Database by computer to collect controlled clinical studies on the efficacy and safety of unilateral BE-TLIF and MIS-TLIF in lumbar degenerative diseases from database establishment to May 2023. Two researchers screened the literature, extracted data and evaluated the risk of bias of the included studies, recorded the authors, and sample size, and extracted the intraoperative blood loss, operation time, postoperative drainage, Oswestry disability index, Visual analogue scale, lumbar lordosis, disk height, hospital length stay, fusion rate, and complications in each study. Meta-analysis was performed using Revman 5.4 software provided by Cochrane Library.

Results A total of 14 cohort studies with a total of 1007 patients were included in this study, including 472 patients in the BE-TLIF group and 535 patients in the MIS-TLIF group. The BE-TLIF group had lower intraoperative blood loss than the MIS-TLIF group [mean difference (MD) = -78.72, 95% CI (-98.47, -58.97), P < 0.00001] and significantly reduced postoperative drainage than the MIS-TLIF group [MD = -43.20, 95% CI (-56.57, -29.83), P < 0.00001], and the operation time was longer than that of the MIS-TLIF group [MD = 22.68, 95% CI (12.03, 33.33), P < 0.0001]. Hospital length stay in BE-TLIF group was significantly less than that in MIS-TLIF group [MD = -1.20, 95% CI (-1.82, -0.57), P = 0.0002].

[†]Haopeng Luan and Cong Peng have contributed equally to this work.

*Correspondence: Xinghua Song songxinghua19@163.com Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

Conclusion Compared with MIS-TLIF, BE-TLIF for lumbar degenerative diseases has the advantages of less intraoperative blood loss, less early postoperative low back and leg pain, shorter postoperative hospital length stay, and faster early functional recovery.

Keywords Unilateral biportal endoscopic, Transforaminal lumbar interbody fusion, Lumbar degenerative diseases

Introduction

In recent years, minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) has emerged as a standard surgical technique for minimally invasive lumbar interbody fusion. Its widespread adoption in clinical practice can be attributed to its minimal invasiveness, quick postoperative recovery, and relatively short learning curve [1, 2]. However, MIS-TLIF has its drawbacks. Due to the depth of the surgical site, the distractor blade cannot fully retract all soft tissues. This can allow some tissues to obstruct the surgical view, complicating the procedure. Additionally, the distractor blades can overstretch the paravertebral muscles, causing ischemia, which may hinder postoperative recovery [3]. As spinal endoscopic techniques continue to gain popularity and widespread use, the unilateral biportal endoscopic (UBE) technique has been progressively integrated into clinical practice. Since its visualization and operational components are situated in separate channels, they don't interfere with each other. This provides a broad field of view, making device manipulation easier and ensuring thorough nerve decompression [4]. Heo et al. [5] first applied UBE technique to complete lumbar interbody fusion in 2017 and obtained good clinical results. There is no previous meta-analysis related to the two. The purpose of this study is to analyze and compare the clinical efficacy of unilateral biportal endoscopic transforaminal lumbar interbody fusion (BE-TLIF) and MIS-TLIF in the treatment of lumbar degenerative diseases and to explore a more suitable minimally invasive lumbar fusion.

Methods

This meta-analysis followed the Cochrane handbook for conducting and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting [6, 7]. Two authors separately conducted literature retrieval, study eligibility, data extraction, and quality assessment with inconsistency solved by discussion and decided by the corresponding author.

Literature search

We searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Database, and Wei Pu Database by computer to collect controlled clinical studies on the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion (BE-TLIF) and minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in lumbar degenerative diseases from database establishment to May 2023. We restricted the language to English and Chinese. By preserving the literature that offered the most comprehensive information for overlapping patients, information duplication was avoided. The brief retrieval formula was "(unilateral biportal endoscopic) AND (lumbar) AND (fusion)".

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) patients treated with BE-TLIF or MIS-TLIF for lumbar degenerative diseases and (2) the literature reported one of the following: intraoperative blood loss, operation time, postoperative drainage, Oswestry disability index (ODI), Visual analogue scale (VAS), lumbar lordosis (LL), disk height (DH), hospital length stay, fusion rate, and complications.

Exclusion criteria were as follows: (1) combined with lumbar infectious diseases, neoplastic diseases or lumbar fractures and other diseases; (2) the index level with a history of previous lumbar spine surgery; (3) review, meeting, expert opinion, case report, literature that could not obtain the full text; and (4) animal experiments and in vitro/biomechanical studies.

Literature screening and data extraction

Two investigators independently screened the literatures according to the inclusion and exclusion criteria, extracted the data, and cross-checked. In case of any disagreement, the disagreement was discussed and resolved. If necessary, the opinion of the third investigator was solicited, and the information was extracted using a predesigned data extraction form. The main information extracted from the data included: (1) general information about the included studies, including the title, author, publication year, etc.; (2) study characteristics, including the study region, sample size, age, operation time, followup time, etc.; (3) outcome measures of interest included intraoperative blood loss, operation time, postoperative drainage, ODI, VAS, LL, DH, hospital length stay, fusion rate and complications; and (4) key elements of bias risk evaluation, including the selection of study population, comparability between groups, and measurement of exposure factors.

Literature quality evaluation

The risk of bias evaluation of the included literatures was independently completed by two evaluators and cross-checked. If there was disagreement on the evaluation results of the literatures, the third party intervened to assist in the discussion and decision. Cochrane Handbook recommended 5.4 Bias Risk Assessment Tool was used to assess the quality of literatures, including sequence generation, allocation concealment, blinding, data integrity, selective reporting, and other potential biases, and the judgment of deviations was expressed as "low risk", "high risk" or "unclear risk". The Newcastle–Ottawa Scale (NOS) risk bias assessment criteria were used to assess the quality of the cohort study (CS) literature, and articles with a total score of \geq 7 were regarded as high-quality articles.

Statistical analysis

Meta-analysis of the data from the included articles was performed using RevMan 5.4 software. Continuous variables were expressed as mean difference (MD) and dichotomous variables as odds ratio (OR), and the size of each pooled effect size and its 95% confidence interval (CI) were calculated. Heterogeneity was analyzed using the Chi-square test, and the size of heterogeneity was judged based on the I^2 value. When P > 0.1 or $I^2 \le 50\%$, heterogeneity between studies was not significant and fixed effect model was used for analysis; if $P \le 0.1$ or $I^2 > 50\%$, heterogeneity between studies was significant, and random effect model was used for analysis.

Results

Literature screening procedure and results

In this study, 263 papers were obtained through a preliminary search, 132 repeated publications were eliminated by software, titles, and abstracts were read, and 103 papers that obviously did not meet the inclusion criteria were eliminated. After careful reading of the full text and quality evaluation, 14 unqualified papers were further excluded, and 14 qualified papers [3, 8–20] were finally included. The paper screening process is presented in Fig. 1. A total of 1007 patients were included, including 472 patients in the BE-TLIF group and 535 patients in the MIS-TLIF group. The main characteristics of the included studies are presented in Table 1.

Quality analysis of included studies

Risk assessment for the 14 cohort studies included in the analysis was conducted using the Cochrane Risk of Bias tool and is presented in Fig. 2. The quality of nonrandomized controlled trials was assessed using the Newcastle–Ottawa Scale (NOS). All included studies scored between 7 and 9 points, indicating high quality. Table 2 provides a summary of the quality scores for each study.

Meta-analysis results Operation time

A total of 13 studies used operation time as an outcome measure, with 400 patients in the BE-TLIF group and 462 patients in the MIS-TLIF group. The heterogeneity test (P < 0.00001, $I^2 = 96\%$) suggested that there was significant heterogeneity between the studies, and a meta-analysis using a random-effects model showed that: [MD = 22.68, 95% CI (12.03, 33.33), P < 0.0001] (Fig. 3), The results showed that the operation time was longer in BE-TLIF compared to MIS-TLIF.

Intraoperative blood loss

Intraoperative blood loss was counted in 11 studies, with 338 patients in the BE-TLIF group and 372 patients in the MIS-TLIF group. The heterogeneity test (P < 0.00001, $I^2 = 97\%$) suggested that there was significant heterogeneity between the studies. The results showed that intraoperative blood loss in the BE-TLIF group was significantly lower than that in the MIS-TLIF group [MD=-78.72, 95% CI (-98.47, -58.97), P < 0.00001] (Fig. 4), indicating that BE-TLIF surgical approach had a certain effect on the reduction of intraoperative blood loss in patients.

Postoperative drainage

Postoperative drainage was reported in six papers, heterogeneity test result P < 0.00001; $I^2 = 93\%$. There was significant heterogeneity across the studies. The results showed that postoperative drainage in BE-TLIF group was significantly less than that in MIS-TLIF group [MD=-43.20, 95% CI (-56.57, -29.83), P < 0.00001] (Fig. 5).

Pain evaluation

Preoperative back VAS scores were reported in 11 papers, and heterogeneity test results showed P=0.90; $I^2=0\%$. The results showed that preoperative back VAS scores in BE-TLIF group was significantly lower than that in MIS-TLIF group [MD=-0.14, 95% CI (-0.28, -0.00), P=0.04]. The baseline was inconsistent, so postoperative back VAS was not comparable. After remove the study by Kong et al. [11] there was no significant difference in mean preoperative back VAS between the two groups [MD=-0.10, 95% CI (-0.25, 0.04), P=0.17], and there was no heterogeneity between studies (P=0.93; $I^2=0\%$). So, only 10 studies were included for comparison. Preoperative leg VAS scores were reported in 12 papers, and heterogeneity test results showed P=0.83; $I^2=0\%$. The



Fig. 1 Flowchart illustrating the literature search and the selection of included studies

results showed that there was no significant difference in preoperative leg VAS score between BE-TLIF and MIS-TLIF group [MD = -0.01, 95% CI (-0.15, 0.12), P=0.86].

Back VAS scores at early postoperative were reported in 12 papers, and heterogeneity test results showed P < 0.00001; $I^2 = 92\%$. The results showed that back VAS score at early postoperative in BE-TLIF group was significantly lower than that in MIS-TLIF group [MD=-0.82, 95% CI (-1.21, -0.44), P < 0.0001]. Leg VAS scores at early postoperative were reported in 10 papers, and heterogeneity test results showed P < 0.0001; $I^2 = 76\%$. The results showed that leg VAS score at early postoperative in BE-TLIF group was significantly lower than that in MIS-TLIF group [MD=-0.16, 95% CI (-0.28, -0.04), P=0.007] (Fig. 6, Fig. 7).

Oswestry disability index

Preoperative Oswestry disability index was reported in 12 papers, and heterogeneity test results showed P=0.11; $I^2=35\%$. The results showed that there was no significant difference in the preoperative Oswestry disability index between BE-TLIF and MIS-TLIF group [MD=-0.52, 95% CI (-1.61, 0.56), P=0.34].

Study	Study design	Country	Group	۲	Age (years)	N(Male/Female)	Operation level (<i>n</i>)	Follow-up (Month)	Diagnosis (<i>n</i>)	Complication (n)
Heo [15]	Retrospective	Korea	BE-TLIF	23	61.4±9.4	7/16	L3-4(3);L4-5(17); L5-S1(3)	13.4±2.5	Degenerative spondylolis- thesis, lsthmic spondylolis- thesis, central stenosis with instability; Central stenosis with concomitant foraminal stenosis(23)	Epidural hematoma(1); Cage subsidence(1)
			MIS-TLIF	46	63.5 ± 10.5	19/27	L3-4(4),L4-5(29); L5-S1(13)	13.4±2.5	Degenerative spondylolis- thesis; lsthmic spondylolis- thesis; Central stenosis with instability; Central stenosis with concomitant foraminal stenosis(46)	Dural tear(1); Epidural hematoma(1); Superficial wound infection(1); Deep vein Thrombosis(1); Cage subsidence(2)
Kim [21]	Retrospective	Korea	BE-TLIF	32	70.5±8.26	17/15	L2-3(1);L3-4(3); L4-5(20);L5- S1(8)	27.2 ± 5.4	Degenerative spon- dylolisthesis(26); lsthmic spondylolisthesis(6)	Epidural hematoma(1); Transient palsy(1)
			MIS-TLIF	55	67.3±10.7	25/30	L3-4(2);L4-5(46); L5-S1(7)	31.5 ± 7.3	Degenerative spon- dylolisthesis(48); lsthmic spondylolisthesis(7)	Epidural hematoma(1); Transient palsy(2)
Kang [8]	Retrospective	Korea	BE-TLIF	47	66.87 ± 10.41	17/30	L2-3(4);L3-4(7); L4-5(34);L5-51(20)	14.5±2.3	Lumbar spinal stenosis; Spondylolisthesis(47)	Incomplete decompres- sion(1); Hematoma(2); Dural tear(3)
			MIS-TLIF	32	66.38±9.45	17/15	L2-3(1);L3-4(9); L4-5(22);L5-S1(11)	15.78±3.16	Lumbar spinal stenosis; Spondylolisthesis(32)	Incomplete decompres- sion(2); Hematoma(1); Dural tear(1);Infection (1)
Gatam [16]	Retrospective	Indonesia	BE-TLIF	72	55.1±5.12	26/46	L3-4(8);L4-5(56); L5-51 (8)	12	Single level degenerative spondylolisthesis(72)	Dural tear (3)
			MIS-TLIF	73	52.3±6.13	28/45	L3-4(10);L4-5(48); L5-51(15)	12	Single level degenerative spondylolisthesis(73)	Postoperative infection(2); Cage subsidence(2)
Zhu [14]	Retrospective	China	BE-TLIF	35	50.94±12.12	16/19	L4-5(28);L5-S1(7)	15.29±1.98	Lumbar spinal stenosis(19);Lumbar disk herniation(7);Spondylolist hesis(9)	Transient lower extremity numbness(2)
			MIS-TLIF	4	53.44±14.37	19/22	L3-4(2);L4-5(25); L5-51(14)	16.12±2.59	Lumbar spinal stenosis(21);Lumbar disk herniation(13);Spondylolis thesis(7)	Transient lower extremity numbness(2);Epidural hematoma(1)

 Table 1
 The basic characteristics of the included studies

Table 1 🤅	continued)									
Study	Study design	Country	Group	۲	Age (years)	N(Male/Female)	Operation level (n)	Follow-up (Month)	Diagnosis (<i>n</i>)	Complication (<i>n</i>)
Ni [20]	Retrospective	China	BE-TLIF	27	50.4 ± 11.4	9/18	L2-3(2),L3-4(0),L4-5(18),L5- 51(7)	13.3±1.0	Lumbar disk herniation with instability(15), Lumbar spinal stenosis with insta- bility(12)	No complications
			MIS-TLIF	33	53.4±13.5	15/18	L2-3(0);L3-4(3);L4-5(21);L5- 51(9)	13.4±1.2	Lumbar disk herniation with instability(21); Lumbar spinal stenosis with insta- bility(12)	No complications
Jiang [1 <mark>9</mark>]	Retrospective	China	BE-TLIF	25	63.28±8.51	9/16	L4-5(24);L5-S1(1)	NR	Single-segment lumbar stenosis with instability(25)	No complications
			MIS-TLIF	25	59.68±10.38	8/17	L4-5(23);L5-S1(2)	NR	Single-segment lumbar stenosis with instability(25)	No complications
Song [12]	Retrospective	China	BE-TLIF	28	54.7±10.0	10/18	L3-4(1);L4-5(22); L5-S1(5)	14.1 ± 1.5	Meyerding ISpondylolis- thesis(28)	Slight decrease in muscle strength(1)
			MIS-TLIF	28	56.3±11.6	8/20	L3-4(1);L4-5(20); L5-S1(7)	14.3 ± 1.4	Meyerding ISpondylolis- thesis(28)	Transient lower extremity numbness(1)
Kong [11]	Retrospective	China	BE-TLIF	35	55.1(39–70)	13/22	L2-3(1),L3-4(5); L4-5(17);L5-51(10); L4-51(2)	14.7 ± 2.5	Lumbar disk herniation with spinal stenosis(15); Lumbar spinal stenosis(12); Lumbar spinal stenosis with mild spondylolisthe- sis(8)	Dural tear(1); Postoperative epidural hematoma(1)
			MIS-TLIF	40	56.0(41–73)	18/22	L1-2(1);L2-3(4); L3-4(7);L4-5(15); L5-S1(12);L4-S1(1)	15.0±3.4	Lumbar disk herniation with spinal stenosis(9); Lumbar spinal stenosis(15); Lumbar spinal stenosis with mild spondylolisthe- sis(16)	Dural tear(1); Postoperative epidural hematoma (1); Infection(1)
Song [9]	Retrospective	China	BE-TLIF	25	52.36±10.69	9/16	L3-4(2);L4-5(13); L5-S1(10)	14.04±1.51	Lumbar spinal stenosis; Lumbar disk herniation; Spondylolisthesis(25)	Transient lower extremity numbness(1)
			MIS-TLIF	24	56.38±10.53	8/16	L3-4(2);L4-5(10); L5-51(12)	14.79±1.59	Lumbar spinal stenosis,Lumbar disk herniation; Spondylolis- thesis(24)	Transient lower extremity numbness(4)

Table 1 (c	continued)									
Study	Study design	Country	Group	۲	Age (years)	N(Male/Female)	Operation level (<i>n</i>)	Follow-up (Month)	Diagnosis (<i>n</i>)	Complication (n)
Huang [10]	Retrospective	China	BE-TLIF	33	60.13±7.36	22/16	L4-5(28);L5-51(10)	Ж	Degenerative Spondylolisthesis(19); Central stenosis with seg- mental Instability(5); Isthmic Spondylolisthesis(4); Lum- bar disk herniation with spinal stenosis(10)	Dural tear(2)
			MIS-TLIF	4	59.68 ± 6.94	26/18	L3-4(1); L4-5(30);L5-51(13)	Ж	Degenerative Spondylolisthesis(22); Central stenosis with seg- mental Instability(7); Isthmic Spondylolisthesis(6); Lum- bar disk herniation with spinal stenosis(9)	Transient neurologic symp- tom(2)
Heo [17]	Retrospective	Korea	BE-TLIF	32	65.2±19.5	10/22	L4-5(27);L5-51(5)	13.9±2.6	Degenerative spon- dylolisthesis(20); Isthmic spondylolisthesis(5); Cen- tral stenosis(4); Foraminal stenosis(3)	Postoperative epidural hematoma(2);Pneumonia (1);Transient neurologic symptoms(1);Postoperative ileus(1);Dura tear(1); Wound dehiscence (1); Cage subsidence(4)
			MIS-TLIF	4	62.3±10.6	16/25	L4-5(30);L5-51(11)	15.0±3.3	Degenerative spon- dylolisthesis(27); Isthmic spondylolisthesis(5); Cen- tral stenosis(5); Foraminal stenosis(2); Recurrent disk herniation(2)	Postoperative epidural hematoma(1);Transient neu- rologic symptom(1); Cage subsidence(1)
Yu [18]	Retrospective	China	BE-TLIF	23	60.8(45–74)	11/12	L3-4(3);L4-5(11);L5-S1(9)	38.96±3.17	Degenerative spon- dylolisthesis(16); lsthmic spondylolisthesis(7)	Cage subsidence(2); Dural tear(1)
			MIS-TLIF	18	60.7(46–71)	8/10	L3-4(3);L4-5(8);L5-S1(7)	39.50±3.35	Degenerative spon- dylolisthesis(14); Isthmic spondylolisthesis(4)	Dural tear(2); Cage subsid- ence(1); Postoperative infection(1)
Yang [13]	Retrospective	China	BE-TLIF	30	49.3±3.5	12/18	L3-4(6);L4-5(15);L5-S1(9)	NR	Single-level lumbar spinal stenosis; Single-level lum- bar disk herniation(30)	Dural tear(1); Transient neu- rologic symptom(1)
			MIS-TLIF	35	50.9±3.6	20/15	L3-4(7);L4-5(21);L5-S1(7)	NR	Single-level lumbar spinal stenosis; Single-level lum- bar disk herniation(35)	Transient neurologic symptom(1); Postoperative epidural hematoma(1)
BE-TLIF = unil	ilateral biportal enc	doscopic tra	Insforaminal	lumbã	ar interbody fusi	on; MIS-TLIF = minima	ally invasive transforaminal lum	hbar interbody fusion; NR =	= not reported	



Fig. 2 Risk of bias graph for each included study

Postoperative Oswestry disability index was reported in 11 papers, and heterogeneity test results showed P < 0.00001; $I^2 = 92\%$. The results showed that back Oswestry disability index at early postoperative in BE-TLIF group was significantly lower than that in MIS-TLIF group [MD=-3.33, 95% CI (-5.47, -1.19), P=0.002] (Fig. 8).

Lumbar lordosis

Preoperative lumbar lordosis was reported in 4 papers, and heterogeneity test results showed P=0.79; $I^2=0\%$. The results showed that there was no significant difference in preoperative lumbar lordosis between BE-TLIF and MIS-TLIF group [MD=0.15, 95% CI (-0.79, 1.09), P=0.76].

Postoperative lumbar lordosis was reported in three papers, and heterogeneity test results showed P=0.47; $I^2=0\%$. The results showed that there was no significant difference in postoperative lumbar lordosis between BE-TLIF and MIS-TLIF group [MD=-0.12, 95% CI ($-1.70\ 1.46$), P=0.88] (Fig. 9).

Disk height

Preoperative disk height was reported in four papers, and heterogeneity test results showed P < 0.00001; $I^2 = 89\%$. The results showed that there was no significant difference in preoperative disk height between BE-TLIF and MIS-TLIF group [MD = -0.34, 95% CI (-1.52, 0.84), P = 0.57].

Table 2 Quality Assessment Using the Newcastle–Ottawa Quality Assessment Scale for Each Non-Randomized Controlled Trial

Variable	Heo [15]	Kim [<mark>2</mark> 1]	Kang [<mark>8</mark>]	Gatam [16]	Zhu [14]	Ni [<mark>20</mark>]	Jiang [<mark>19</mark>]	Song [12]	Kong [11] 5	song [<mark>9</mark>]	Huang [10]	Heo [<mark>17</mark>]	Yu [18]	Yang [<mark>13</mark>]
Selection														
Representativeness of exposed cohort		. 	-	-	-	-	. 	-			-	-	-	-
Selection of non-exposed cohort	-		-	-	-	-	_	-		_	-	-	-	-
Ascertainment of exposure	, -	-	-	, -	-	-		-			-	, -	-	-
Demonstration that outcome of interest was not present at start of study	-			-			-	_			_	-	-	
Comparability														
Study controlled for age or gender	, -	-	-		-	_		-			_	-	-	_
Study controlled for any additional factor	-		-					-	-	_				-
Outcome														
Assessment of outcome	-	-	-	, -	-	-	-	, -		_	-	-	-	.
Follow-up long enough for outcomes to occur	-			-	-	-		-		_	-		-	
Adequacy of follow-up of cohort	, -	-	-	_	-	_	-	-			-	-	-	—
Total	6	8	00	8	7	7	8	6	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~	00	6	~	8
														1

	В	E-TLIF		M	S-TLIF			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Heo et al 2019	152.4	9.6	23	122.4	13.1	46	8.5%	30.00 [24.55, 35.45]	-
Heo et al 2023	150.2	8.1	32	123.9	12.8	41	8.5%	26.30 [21.48, 31.12]	-
Huang et al 2023	154.23	13.7	38	131.88	15.02	44	8.4%	22.35 [16.13, 28.57]	-
Jiang et al 2022	178	11.63	25	128.8	10.1	25	8.5%	49.20 [43.16, 55.24]	-
Kang et al 2021	170.46	34.81	47	135.7	42.88	32	7.0%	34.76 [16.88, 52.64]	
Kim et al 2021	169.5	24.9	32	173	47.1	55	7.4%	-3.50 [-18.65, 11.65]	
Kong et al 2022	173.7	20.6	35	158.8	14.2	40	8.3%	14.90 [6.78, 23.02]	-
Ni et al 2022	274.3	88.2	27	181.8	58.7	33	4.0%	92.50 [53.67, 131.33]	
Song et al 2022	144	24.7	28	109	28.4	28	7.6%	35.00 [21.06, 48.94]	
Song et al 2023	158	25.03	25	145.67	24.82	24	7.6%	12.33 [-1.63, 26.29]	<u>–</u> –
Yang et al 2023	119.4	6.3	30	120.3	6.4	35	8.6%	-0.90 [-3.99, 2.19]	†
Yu et al 2023	144.39	13.81	23	135.83	13.07	18	8.3%	8.56 [0.30, 16.82]	
Zhu et al 2021	153.29	38.42	35	146.49	25.78	41	7.4%	6.80 [-8.18, 21.78]	
Total (95% CI)			400			462	100.0%	22.68 [12.03, 33.33]	•
Heterogeneity: Tau ² =	339.92; 0	Chi² = 3 ²	14.76, c	lf = 12 (F	o < 0.00	001); l²	= 96%	-	
Test for overall effect:	Z = 4.17	(P < 0.0	001)						
			,						Favours (BE-ILIF) Favours (MIS-ILIF)

Fig. 3 Forest plot of operation time



Fig. 4 Forest plot of intraoperative blood loss

	E	BE-TLIF		M	S-TLIF			Mean Difference		Mean D	ifference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Rand	<u>om, 95% C</u>	1	
Huang et al 2023	62.36	10.31	38	88.97	13.31	44	22.8%	-26.61 [-31.73, -21.49]		-			
Jiang et al 2022	45.4	8.73	25	102.84	18.24	25	21.8%	-57.44 [-65.37, -49.51]					
Kang et al 2021	163.81	121.04	47	225.81	101.4	32	5.6%	-62.00 [-111.31, -12.69]					
Ni et al 2022	95.7	79.7	27	125.4	113.1	33	5.7%	-29.70 [-78.62, 19.22]			+		
Song et al 2023	25.04	13.14	25	84.79	21.95	24	20.8%	-59.75 [-69.93, -49.57]					
Yang et al 2023	51	7.1	30	81.1	7	35	23.3%	-30.10 [-33.54, -26.66]					
Total (95% CI)			192			193	100.0%	-43.20 [-56.57, -29.83]		•			
Heterogeneity: Tau ² =	196.94; 0	Chi² = 72	.37, df =	= 5 (P < (0.00001); I² = 9	3%		-100	-50	1	50	100
Test for overall effect:	Z = 6.33	(P < 0.00	001)						100	Favours [BE-TLIF]	Favours [MIS-TLIF]

Fig. 5 Forest plot of postoperative drainage

Postoperative disk height was reported in three papers, and heterogeneity test results showed P=0.63; $I^2=0\%$. The results showed that there was no significant difference in postoperative disk height between BE-TLIF and MIS-TLIF group [MD=-0.04, 95% CI (-0.340.26), P=0.81] (Fig. 10).

Fusion rate

Fusion rate were reported in 11 papers, and heterogeneity test results showed P=1.00; $I^2=0\%$. The results showed that there was no significant difference in fusion rate between BE-TLIF and MIS-TLIF group [OR=1.10, 95% CI (0.71, 1.71), P=0.66]. Five of the 11 articles used



Fig. 6 Forest plot of back VAS



Fig. 7 Forest plot of leg VAS

Bridwell grading [21] to assess fusion rates, three did not describe the method of assessment, and the remaining three used Suk grading [22], Eck grading [23], Brantigan and Steffee criteria [24] to assess fusion rates, respectively (Fig. 11). Bridwell grading was used in 5 articles, and heterogeneity test results showed P=0.98; $I^2=0\%$. The results showed that there was no significant difference in fusion rate between BE-TLIF and MIS-TLIF group [OR = 0.99, 95% CI (0.50, 1.96), P = 0.98].

Hospital length stay

Hospital length stay was reported in eight papers, heterogeneity test result P < 0.0001; $I^2 = 79\%$. There was significant heterogeneity across the studies. The results showed



Fig. 8 Forest plot of ODI

that hospital length stay in BE-TLIF group was significantly less than that in MIS-TLIF group [MD=-1.20, 95% CI (-1.82, -0.57), P=0.0002] (Fig. 12).

Complications

Total complications were reported in 14 papers, and heterogeneity test results showed P=0.98; $I^2=0\%$. The results showed that there was no significant difference

in total complications between BE-TLIF and MIS-TLIF group [OR=0.63, 95% CI (0.39, 1.04), P=0.07]. Dural tears were reported in 11 papers, and heterogeneity test results showed P=0.73; I^2 =0%. The results showed that there was no significant difference in dural tears between BE-TLIF and MIS-TLIF group [OR=1.68, 95% CI (0.69, 4.06), P=0.25]. Transient neurologic symptoms were reported in 11 papers, and heterogeneity test



BE-TLIE MIS-TLIF Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI 1.8.1 Preoperative Kang et al 2021 8.39 2.7 47 782 249 32 6.8% 0.57 [-0.59, 1.73] Kong et al 2022 8.97 1.26 35 8.72 1.02 40 12.2% 0.25 [-0.27, 0.77] Ni et al 2022 7.99 1.27 27 9.87 1.31 33 10.9% -1.88 [-2.54, -1.22] Yu et al 2023 8.78 1.31 23 8.94 1.66 18 8.4% -0.16 [-1.10, 0.78] Subtotal (95% CI) -0.34 [-1.52, 0.84] 132 123 38.3% Heterogeneity: Tau² = 1.26; Chi² = 28.47, df = 3 (P < 0.00001); I² = 89% Test for overall effect: Z = 0.56 (P = 0.57) 1.8.2 Postoperative Kang et al 2021 10.3 1.9 47 10.27 3.09 32 6.5% 0.03 [-1.17, 1.23] 0.03 [-0.32, 0.38] Kong et al 2022 10.32 0.76 35 10.29 0.77 40 13.8% Ni et al 2022 10.2% -0.36 [-1.09, 0.37] 11.77 1.57 27 12.13 1.23 33 Subtotal (95% CI) 109 105 30.5% -0.04 [-0.34, 0.26] Heterogeneity: Tau² = 0.00; Chi² = 0.92, df = 2 (P = 0.63); I² = 0% Test for overall effect: Z = 0.25 (P = 0.81) 1.8.3 Final follow-up 0.07 [-0.28, 0.42] Kong et al 2022 10.11 0.74 35 10.04 0.82 13.7% 40 Ni et al 2022 11.28 1.54 27 11.55 1.18 33 10.4% -0.27 [-0.98, 0.44] Yu et al 2023 7.0% -0 70 [-1 82 0 42] 9.91 1.68 23 10.61 1.91 18 Subtotal (95% CI) 85 91 31.2% -0.06 [-0.39, 0.26] Heterogeneity: Tau² = 0.01; Chi² = 2.11, df = 2 (P = 0.35); I² = 5% Test for overall effect: Z = 0.38 (P = 0.70) Total (95% CI) 319 100.0% -0.25 [-0.65, 0.15] 326 Heterogeneity: Tau² = 0.28; Chi² = 34.48, df = 9 (P < 0.0001); l² = 74% -2 -1 0 Test for overall effect: Z = 1.21 (P = 0.23) Favours [BE-TLIF] Favours [MIS-TLIF] Test for subgroup differences: $Chi^2 = 0.23$. df = 2 (P = 0.89). I² = 0%

Fig. 10 Forest plot of DH



 Total (95% Cl)
 257
 283
 100.0%

 Heterogeneity: Tau² = 0.58; Chi² = 32.80, df = 7 (P < 0.0001); l² = 79%
 Test for overall effect: Z = 3.75 (P = 0.0002)



Fig. 12 Forest plot of hospital length stay

results showed P=0.92; $I^2=0\%$. The results showed that there was no significant difference in transient neurologic symptoms between BE-TLIF and MIS-TLIF group [OR=0.59, 95% CI (0.25, 1.37), P=0.22]. Among the references included in this article, 65.5% of the patients presented with dural tear and transient neurological symptoms in the BE-TLIF group and 43.7% of the patients presented with dural tear and transient neurological symptoms in the MIS-TLIF group, which accounted for 51.9% of the patients with overall complications in both groups (Fig. 13).

Heterogeneity and sensitivity analysis

-1.20 [-1.82, -0.57]

The analysis revealed high heterogeneity in intraoperative blood loss, postoperative drainage and operation time. To assess the impact of heterogeneity on the results, a sensitivity analysis was conducted by removing individual studies from the analysis of operation time. The findings

Study or Subgroup	Example T	- 4 - 1 - 1		T-4-1	147-1-1-4	MILL Flored OFM OF	MILL Floor d. 059/ OI
1.11.1 Total Complice	<u> </u>	otal E	vents	ı otal	weight	m-H, Fixed, 95% Cl	M-H. Fixed, 95% Cl
Gatam et al 2021	3	72	4	73	4,2%	0.75 [0.16. 3.48]	
Heo et al 2019	2	23	6	46	4.1%	0.63 [0.12, 3.42]	
Heo et al 2023	3	32	11	41	9.8%	0.28 [0.07, 1.12]	
Huang et al 2023	2	38	2	44	2.0%	1.17 [0.16, 8.71]	
Jiang et al 2022	0	25	0	25		Not estimable	
Kang et al 2021	6	47	5	32	5.8%	0.79 [0.22, 2.85]	
Kim et al 2021	2	32	3	55	2.3%	1.16 [0.18, 7.31]	
Kong et al 2022	2	35	3	40	2.9%	0.75 [0.12, 4.75]	
Ni et al 2022	0	27	0	33		Not estimable	
Song et al 2022	1	28	1	28	1.1%	1.00 [0.06, 16.82]	
Song et al 2023	1	25	4	24	4.4%	0.21 [0.02, 2.02]	
Yang et al 2023	2	30	2	35	1.9%	1.18 [0.16, 8.92]	
Yu et al 2023	3	23	4	18	4.4%	0.53 [0.10, 2.72]	
Zhu et al 2021	2	35	3	41 525	2.9%	0.77 [0.12, 4.88]	
Subtotal (95% CI)		472		535	45.7%	0.63 [0.39, 1.04]	•
I otal events	29	(D - 0	48	- 00/			
Test for overall effect:	7 = 1.81 (P =	(F = 0 = 0.07)	.90), 1	- 0 %			
	L = 1.01 (i =	0.07)					
1.11.2 Dural tear							
Gatam et al 2021	3	72	0	73	0.5%	7 40 [0 38, 145 93]	
Heo et al 2019	ō	23	1	46	1.1%	0.65 [0.03, 16,46]	
Heo et al 2023	0	32	1	41	1.5%	0.42 [0.02, 10.54]	
Huang et al 2023	2	38	Ó	44	0.5%	6.10 [0.28, 131.02]	
Kang et al 2021	3	47	1	32	1.2%	2.11 [0.21, 21.28]	
Kim et al 2021	0	32	0	55		Not estimable	
Kong et al 2022	1	35	1	40	1.0%	1.15 [0.07, 19.05]	
Ni et al 2022	0	27	0	33		Not estimable	
Yang et al 2023	1	30	0	35	0.5%	3.61 [0.14, 91.96]	— ·
Yu et al 2023	1	23	2	18	2.4%	0.36 [0.03, 4.37]	
Zhu et al 2021	0	35	0	41		Not estimable	
Subtotal (95% CI)	:	394		458	8.7%	1.68 [0.69, 4.06]	
Total events	11		6				
Heterogeneity: Chi ² =	4.46, df = 7 (P = 0.7	'3); ² =	0%			
Test for overall effect:	Z = 1.15 (P =	= 0.25)					
1 11 2 Infoction							
Cotom at al 2004	~	70	~	70	2.00/	0.00.00.01.4.00	
Heo et al 2021	0	22	2	13	2.8%	0.20 [0.01, 4.18]	
Heo et al 2019	0	23 32	1	40	1.1%	0.00 [0.03, 10.46]	
liona ot al 2023	0	32		25	1.5%	0.42 [0.02, 10.54]	
Kang et al 2022	0	47	1	20	2.0%		
Kim et al 2021	0	32		55	2.0%	Not estimable	
Kong et al 2022	0	35	1	40	1.5%	0.37 [0.01 9.40]	
Nietal 2022	0	27	'n	33	1.070	Not estimable	
Song et al 2023	Ő	25	ő	24		Not estimable	
Yu et al 2023	0	23	1	18	1.8%	0.25 [0.01, 6.47]	
7bu at al 2021	ő	35	o.	41	1.070	Not estimable	
Subtotal (95% CI)	:	376	-	428	10.6%	0.31 [0.08, 1.15]	
Total events Heterogeneity: Chi ² = 1 Test for overall effect:	0 0.38, df = 5 (Z = 1.75 (P =	376 P = 1.0 = 0.08)	7)0); l² =	428 0%	10.6%	0.31 [0.08, 1.15]	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2019	0 0.38, df = 5 (Z = 1.75 (P = toma 1	376 P = 1.0 = 0.08) 23	7)0); l² = 1	428 0% 46	10.6% 0.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34,26]	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = I Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2023	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1	376 P = 1.0 = 0.08) 23 32	7)0); I ² = 1 2	428 0% 46 41	10.6% 0.7% 1.9%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26]	
The tail 2021 Subtotal (95% CI) Total events Heterogeneity: $Chi^2 = 1$ Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2023 Kang et al 2021	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2	376 P = 1.0 = 0.08) 23 32 47	7 00); I ² = 1 2 1	428 0% 46 41 32	10.6% 0.7% 1.9% 1.3%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87]	
The state 2021 bubbctai (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2023 Kang et al 2021 (im et al 2021	: 0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1	376 P = 1.0 = 0.08) 23 32 47 32	7 00); I ² = 1 2 1 1	428 0% 46 41 32 55	0.7% 1.9% 1.3% 0.8%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84]	
In the tai 2021 is a 2021 in the tai 2021 in the tai 2021 in the tai 2021 is a 2010 in the tai 2021 in the tai 2021 is a 2021 in the tai 2021 is a 2021 in the tai 2022 is a 2022 in the tai 2022 in the tai 2022 in the tai 2022 is a 2022 in the tai 2022 in tai 2022 in the tai 2022 in tai 2022 in the tai 2022 in tai 2022 i	: 0 0.38, df = 5 (Z = 1.75 (P = toma 1 2 1 2 1	376 P = 1.0 = 0.08) 23 32 47 32 35	7)0); ² = 1 2 1 1 1	428 0% 46 41 32 55 40	0.7% 1.9% 1.3% 0.8% 1.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05]	
Subtotal (95% CI) Total events Heterogeneity: Ch ² = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2021 Gang et al 2021 Kim et al 2022	: 0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27	7)0); ² = 1 2 1 1 1 0	428 0% 46 41 32 55 40 33	0.7% 1.9% 1.3% 0.8% 1.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Ch ² = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2023 Kang et al 2021 Kong et al 2021 Kong et al 2022 Ni et al 2022 Song et al 2023	: 0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 1 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25	7 00); l ² = 1 2 1 1 1 0 0	428 0% 46 41 32 55 40 33 24	0.7% 1.9% 1.3% 0.8% 1.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable Not estimable	
In the table of the table of the table of table	; 0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 30	7 00); l ² = 1 2 1 1 1 0 0	428 0% 46 41 32 55 40 33 24 35	0.7% 1.9% 1.3% 1.0% 1.5%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60]	
Lid et al 2021 i Subbotal (95% CI) Total events Heterogeneity: Ch ² = I Test for overall effect: 1.11.4 Epidural hema Heo et al 2023 Kang et al 2021 Kong et al 2021 Kong et al 2022 Song et al 2022 Song et al 2023 Yang et al 2023	: 0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 30 23	7 00); ² = 1 2 1 1 1 1 0 0 1 0	428 0% 46 41 32 55 40 33 24 35 18	0.7% 1.9% 1.3% 0.8% 1.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34 26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60] Not estimable	
Subtail (95% CI) Total events Heterogenetic; Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2021 Kim et al 2021 Kim et al 2021 Ni et al 2022 Song et al 2023 Yu et al 2023 Zu et al 2023	0 0.38, df = 5 (Z = 1.75 (P = 1 2 1 1 1 0 0 0 0 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 30 23 35 27 25 30 23 35	7 00); ² = 1 2 1 1 1 1 0 0 1 0	428 0% 46 41 32 55 40 33 24 35 18 41	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63]	
Subtack (95% Cf) Total events Heterogeneity: Chi ^a = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2021 Kang et al 2021 Kang et al 2022 Song et al 2022 Song et al 2022 Yug et al 2023 Yug et al 2023 Zhu et al 2021 Subtack (95% Cf)	0.38, df = 5 (Z = 1.75 (P = toma 1 2 1 1 0 0 0 0 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 30 23 35 309	7)0); ² = 1 2 1 1 1 1 0 0 1 0 1	428 0% 46 41 32 55 40 33 24 35 18 41 365	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55]	
Jul et al. 2021 Subtotal (95% Cf) Total events Heterogeneity: Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2021 Kong et al 2021 Yang et al 2022 Yang et al 2023 Yang et al 2023 Yang et al 2023 Yang et al 2023 Yang et al 2023 Subtotal (95% Cf) Total events Heterogeneity: Chi ² =	0.38, df = 5 (Z = 1.75 (P = toma 1 1 1 0 0 0 0 0 0 1.30, df = 6 (376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 30 23 35 309 P = 0.9	7 10); ² = 1 2 1 1 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 1 0 0 1 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	428 0% 46 41 32 55 40 33 24 35 18 41 365 0%	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.67] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.01, 9.60] 0.39 [0.34, 2.55]	
Subtact (95% Cf) Total events Heterogenetic, Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2021 Grant et al 2021 Kong et al 2022 Yang et al 2022 Yang et al 2023 Yang et al 2023 Yang et al 2023 Yang et al 2023 Yang et al 2023 Subtacli (95% Cf) Total events Heterogenetic; Chi ² = Test for overall effect:	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	376 P = 1.0 23 32 47 32 35 27 25 30 23 35 30 9 P = 0.9 = 0.88)	7 00); ² = 1 2 1 1 1 1 0 0 1 0 1 8 07); ² =	428 0% 46 41 32 55 40 33 24 35 18 41 365 0%	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.67] 7.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55]	
Subtact (95% Cf) Total events Heterogenetic: Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema Heo et al 2019 Heo et al 2019 Heo et al 2021 Kinn et al 2022 Song et al 2022 Song et al 2022 Song et al 2022 Song et al 2022 Zhu et al 2022 Zhu et al 2023 Zhu et al 2023 Exototal (95% Cf) Total events Heterogenetic: Chi ² = Fest for overall effect:	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0 0 0 0 1.30, df = 6 (Z = 0.15 (P = rologic symp	376 P = 1.0 = 0.08) 23 32 47 32 27 25 30 23 35 309 P = 0.5 = 0.88) Ptoms	7 7 1 2 1 1 1 0 0 1 0 1 8 97); I ² =	428 00% 46 41 32 55 40 33 24 40 35 18 41 365 00%	10.6% 0.7% 1.9% 1.3% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.67] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.33 [0.34, 2.55]	
Link et al. 2021 Link et al. 2021 Total events Helerogenetik: Chi ² = 1 Test for overall effect: 1.11.4 Epidural herma Heo et al 2023 King et al 2023 King et al 2022 Song et al 2022 Yu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Total events Helerogenetik: Chi ² = Test for overall effect: 1.11.5 Transient neur	0 0.38, df = 5 (Z = 1.75 (P = 1 1 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	376 P = 1.0 = 0.08) 23 32 47 32 35 32 47 32 27 25 30 23 35 309 P = 0.9 = 0.88) P = 0.9 = 0.88) ptoms 23	7 7 1 2 1 1 2 1 1 1 1 1 0 0 1 1 8 8 77; i ² =	428 0% 46 41 32 55 40 33 24 35 18 41 365 0%	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.60] 0.38 [0.03, 9.63] 0.39 [0.34, 2.55]	
Subtrait (95% Cf) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al 2021 dong et al 2021 dong et al 2022 Song et al 2022 Yu et al 2022 Yu et al 2022 Yu et al 2023 Yu et al 2023 Total events telerogenetic, Chi ² = Test for overall effect: 1.11.5 Transient neur Heo et al 2013	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 2 1 1 0 0 0 0 0 0 0 0 0 0 1 30, df = 6 (Z = 0.15 (P = tologic symp 0 0 1	376 P = 1.0 23 32 47 32 35 27 25 30 23 35 30 9 P = 0.9 8 30 9 P = 0.9 8 23 32 23 35 30 9	7 7)(0); ² = 1 1 2 1 1 1 1 1 0 0 1 0 1 8 8 7); ² =	428 0% 46 41 32 55 4 33 24 35 18 435 18 365 0%	0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 7.4 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.02, 9.63] 0.33 [0.34, 2.55]	
Link et al. 2021 Link et al. 2021 Total events Heterogeneity: Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema Heo et al. 2023 Kong et al. 2023 Kong et al. 2022 Kong et al. 2022 Song et al. 2023 Yu et al. 2023 Total events Heterogeneity: Chi ² = Test for overall effect: Hete. 2019 Hete al. 2023 Heterogeneity: Chi ² = Test for overall effect: Hete al. 2023 Heterogeneity: Chi ² = Test for overall effect: Hete al. 2023 Heterogeneity: Chi ² = Test for overall effect: Heterogeneity: Chi ² = 1.223 Heterogeneity: Chi ² = 1.223 Hete	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	376 P = 1.0 23 32 47 32 35 27 25 30 23 35 32 30 9 P = 0.9 23 35 30 9 P = 0.9 23 35 30 9	7 7)0); ² = 1 2 1 1 1 1 2 1 1 0 1 0 1 8 8 7); ² =	428 428 40% 46 41 32 55 40 33 24 355 18 41 365 0% 46 41 41 41 41 41 41 41 41 41 41	10.6% 0.7% 1.9% 1.3% 1.0% 1.5% 8.7% 0.9% 2.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] Not estimable Not estimable 0.38 [0.07, 19.05] Not estimable 0.38 [0.07, 9.86] 0.38 [0.02, 9.63] 0.39 [0.34, 2.55]	
Link et al. 2021 Link et al. 2021 Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al. 2014 teo et al. 2021 Kim et al. 2021 Kim et al. 2022 Song et al. 2023 Yu et al. 2023 Total events telerogenetic, Chi ² = Test for overall effect: 1.11.5 Transient neu- teo et al. 2021 Heo et al. 2023 Jiang et al. 2024 Jiang et al. 2024 Jiang et al. 2024 Jiang et al. 2025 Jiang et al. 2025 Jiang et al. 2025 Jiang et al. 2025 J	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 2 1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	376 P = 1.0 23 32 47 32 35 27 25 30 23 35 23 30 9 P = 0.5 30 23 30 9 P = 0.5 30 23 32 33 5 23 34 9 23 32 34 35 23 34 35 23 34 35 23 34 35 23 34 35 23 34 35 35 36 36 37 27 36 37 27 36 37 27 36 37 27 36 37 27 37 37 27 37 37 37 37 37 37 37 37 37 37 37 37 37	7 7 1 2 1 1 2 1 1 1 1 1 0 0 1 0 1 8 2 7); ² = 0 1 2 0 0	428 0% 46 41 32 55 40 33 24 35 58 18 41 365 0% 46 41 44 25 20%	10.6% 0.7% 1.9% 1.9% 1.0% 1.5% 8.7% 0.9% 2.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.374 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.60] 0.38 [0.07, 9.60] 0.39 [0.04, 2.55] Not estimable 1.29 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable	
Line et al 2021 Line et al 2021 Diothol (95% Cf) Total events Heterogeneity: Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema teo et al 2021 Kinn et al 2021 Kinn et al 2021 Kinn et al 2021 Kinn et al 2023 Kinn et al 2023 Line et al 2023 Line et al 2021 Line to et al 2023 Kinn et al 2024 Kinn et al 2024	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 1 1 1 1 0 0 0 0 1 1.30, df = 6 (Z = 0.15 (P = 0 1 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1	P = 1.0. $P = 1.0.$ 23 32 47 32 35 27 27 27 27 23 35 309 $P = 0.5$ 309 $P = 0.5$ 32 32 32 32 32 32 33 32 33 32 33 32 33 32 33 32 33 32 33 32 33 33	7 7 10); ² = 1 2 1 1 1 1 1 1 1 0 0 1 0 1 1 8 8 0 1 2 0 2 2	428 0% 46 41 32 55 40 33 24 35 18 41 365 0% 46 41 44 25 322	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55] Not estimable 1.29 [0.08, 21.46] 0.22 (0.01, 4.74] Not estimable 0.33 [0.03, 9.63] 0.54 [0.55]	
Line et al 2021 Line et al 2021 Line et al 2021 Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al 2019 teo et al 2023 Kang et al 2022 Xang et al 2022 Xang et al 2022 Xang et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Line events Test for overall effect: 1.11.5 Transient neur teo et al 2021 Jiang et al 2023 Jiang et al 2023	$\begin{array}{c} & & & \\ & & & \\ 0 & & \\$	376 P = 1.0. 23 32 47 32 35 30 27 25 30 23 35 30 9 P = 0.9 23 35 30 9 P = 0.9 23 32 23 23 23 23 23 23 23 23 23 23 23	7 7 10); ² = 1 2 1 1 2 1 1 1 1 0 0 1 1 0 1 1 0 1 2 2 2 2	428 428 0% 46 41 32 55 40 33 24 40 35 18 41 365 0% 46 41 41 41 25 55 18 41 365 55 18 55 18 41 25 55 18 41 55 55 18 41 55 55 18 41 55 55 18 41 55 55 18 41 55 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 25 55 18 41 13 26 55 18 41 13 26 55 18 41 26 55 18 41 26 55 55 18 41 26 55 55 55 55 18 41 26 55 55 55 55 55 55 55 55 55 5	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.06] 0.38 [0.02, 9.63] 0.39 [0.28, 2.55] Not estimable 1.29 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 3.76] 0.38 [0.07, 9.82]	
Subtact (95% Cf) Total events telerogenetic, Chi* = 1 Test for overall effect: 1.11.4 Epidural hema Heo et al 2023 Grang et al 2021 Grang et al 2022 Grang et al 2022 Yu et al 2022 Song et al 2023 Yu et al 2022 Subtacta (95% Cf) Total events Heterogenetic; Chi* = Test for overall effect: 1.11.5 Transient neur Heo et al 2023 Yuang et al 2022 Yuang et al 2022 Yuang et al 2021 Yi et al 2022	0.38, df = 5 (0.38, df = 5 (Z = 1.75 (P = 1 1 1 2 1 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 5 (P = 5 (P = 5 (P)) (P = 5 (P)) (P = (P)) (P = (P)) (P)) (P = (P)) (P)	376 P = 1.0 23 32 47 32 27 25 30 23 35 30 23 35 30 9 P = 0.9 = 0.88) ptoms 23 32 23 32 23 35 32 23 35 32 23 35 32 24 35 27 27 32 27 35 27 32 27 35 27 35 27 35 27 35 27 35 27 35 27 35 27 35 35 27 35 35 27 35 35 27 35 35 27 35 35 35 27 35 35 35 35 35 27 35 35 35 27 35 35 35 35 35 35 35 35 35 35 35 35 35	7 7 1 2 1 1 1 1 1 1 1 0 0 1 1 8 8 7 7; ² = 1 2 0 1 2 0 2 2 0 0 4	428 0% 46 41 32 55 40 33 24 35 18 41 365 0% 46 41 44 25 55 33 32	10.6% 0.7% 1.9% 1.3% 0.8% 1.5% 1.5% 8.7%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.49] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.32 [0.04, 24.46] 0.22 [0.04, 27.44] 0.22 [0.04, 27.44] 0.22 [0.07, 9.82] Not estimable	
Line et al 2021 Subtrat (95% Cf) Total events Heterogenetic, Chi ² = 1 Fest for overall effect: 1.11.4 Epiderughemetic, Chi ² = 1 Fest for overall effect: 1.11.4 Epiderughemetic, Chi ² = 1 Hete et al 2023 King et al 2022 Song et al 2022 Yu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Fue et al 2023 Subtotal (95% Cf) Total events Heterogenetic, Chi ² = Test for overall effect: 1.11.5 Transient neur Heterogenetic, Chi ² = 12023 Jiang et al 2023 Jiang et al 2023 Jiang et al 2023 Jiang et al 2023 Jiang et al 2023 Song et al 2022 Song et al 2022 Song et al 2022 Song et al 2022		376 P = 1.0 23 32 47 32 47 32 27 25 30 23 35 309 P = 0.9 23 35 309 P = 0.9 23 35 309 P = 0.9 23 35 23 35 27 27 25 30 23 35 27 27 25 30 23 35 27 27 25 30 23 35 27 27 25 30 23 35 27 27 25 30 23 35 27 27 25 30 23 35 32 23 35 32 23 35 32 23 35 32 23 35 32 23 35 32 27 27 27 23 35 23 32 27 27 27 27 27 27 28 32 27 27 27 28 23 23 23 27 27 27 28 27 28 28 28 28 28 28 28 28 28 28	7 7 1 2 1 1 2 1 1 1 1 1 0 0 1 1 1 2 7 7; ² =	428 0% 46 41 32 55 40 33 32 4 35 18 41 365 0% 46 41 44 25 532 32 8 33 28	10.6% 0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.80] 0.38 [0.02, 9.63] 0.39 [0.08, 21.65] 0.39 [0.03, 3.76] 0.22 [0.01, 4.74] Not estimable 1.29 [0.08, 21.46] 0.32 [0.07, 9.82] Not estimable 1.29 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] Not estimable	
Link et al. 2021 Link et al. 2021 Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema- teo et al. 2014 theo et al. 2023 Grang et al. 2022 Grang et al. 2023 Yu et al. 2023 Grang et al. 2023 Grang et al. 2023 Grang et al. 2022 Grang et al. 2022 Grang et al. 2022 Grang et al. 2022 Grang et al. 2023 Grang et al. 2022 Grang et al. 2022 Grang et al. 2023 Grang et al. 2024 Grang et al. 2024 Gra	$\begin{array}{c} & & & \\ & & & \\ 0 & & & \\ 0 & & & \\ 3 & & & \\ 3 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 1 & & & \\ 1 & & & \\ 1 & & & \\ 1 & & & \\ 1 & & & \\ 0 & & & \\ 1 & & & \\ 0 & & & \\ 0 & & & \\ 1 & & & \\ 0 & & & \\ 0 & & & \\ 1 & & & \\ 0 & & & \\ 1 & & \\ 1 & & & \\ 1 & &$	376 P = 1.0 23 32 47 32 35 27 25 30 35 23 35 23 35 23 30 9 P = 0.9 23 30 9 P = 0.9 23 35 23 35 23 35 23 35 27 25 30 23 35 23 35 27 25 30 23 35 27 25 30 23 35 27 25 30 23 35 27 25 30 23 35 27 25 30 23 35 27 25 30 27 25 30 30 23 30 23 35 27 25 30 27 25 38 27 25 38 27 25 38 27 25 38 27 25 38 27 25 38 25 27 25 38 25 27 25 38 25 27 27 25 38 25 27 27 25 38 25 27 27 27 27 27 25 38 25 27 27 27 27 27 27 27 27 27 27	7 7 1 2 1 1 2 1 1 1 1 2 1 1 1 1 0 0 1 0 1 0	428 0% 46 41 32 55 33 24 35 13 36 13 36 50 33 24 35 50 33 24 35 50 33 24 35 50 33 24 35 50 33 24 41 36 50 33 24 41 36 50 33 24 35 50 33 32 4 35 50 33 32 4 35 50 33 32 4 35 50 33 32 4 35 55 55 33 32 32 4 35 55 33 32 4 35 55 33 32 4 4 35 55 32 24 35 55 32 32 32 4 32 32 32 32 32 32 32 32 32 32 32 32 32	10.6% 0.7% 1.9% 1.3% 0.9% 1.5% 1.5% 2.6% 2.6% 1.1% 4.4%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.75 [0.07, 19.05] Not estimable 0.38 [0.07, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.24, 255] Not estimable 0.39 [0.04, 2.55] 0.33 [0.34, 2.55] Not estimable 0.38 [0.07, 9.82] Not estimable 1.00 [0.06, 16.82] 0.21 [0.02, 20.67]	
Link et al. 2021 Link et al. 2021 Total events Heterogeneity: Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema Heo et al. 2023 Kong et al. 2023 Kong et al. 2022 Via et al. 2022 Via et al. 2022 Via et al. 2022 Via et al. 2023 Via et al. 2022 Song et al. 2023 Via et al. 2024 Via et al. 2025 Via et al. 2024 Via et al. 20	$\begin{array}{c} & & & \\ & & & \\ & & & \\ 0.38, df = 5 (\\ Z = 1.75 (P = \\ 1 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1$	376 P = 1.0 = 0.08) 23 32 47 25 30 23 35 27 30 23 30 23 30 23 309 P = 0.5 c 30 23 32 338 25 347 32 338 25 34 25 36 25 36 25 30 22 23 32 32 32 32 32 32 32 32 32 32 32 33 34	7 7 1 2 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 0 1 1 0 1 2 2 0 0 1 2 2 0 0 1 2 2 0 0 1 2 2 2 0 0 1 2 2 2 2	428 0% 46 41 32 55 40 33 24 41 365 0% 46 41 44 25 50% 0%	0.7% 1.9% 1.3% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.1% 4.4% 1.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] Not estimable Not estimable Not estimable 0.38 [0.07, 19.05] 0.38 [0.07, 9.82] 0.38 [0.02, 9.63] 0.39 [0.34, 2.55] 0.39 [0.03, 3.76] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 3.76] 0.33 [0.03, 3.76] 0.33 [0.03, 3.76] 0.35 [0.07, 9.82] Not estimable 1.00 [0.06, 16.82] Not estimable 0.01 [0.07, 19.59] 1.71 [0.07, 19.59]	
Line et al. 2021 Subtrati (95% Cf.) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al 2014 teo et al 2021 Kim et al 2021 Kim et al 2022 Song et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Line et al 2021 Kim et al 2023 Subtrati (95% Cl) Total events teo et al 2021 Subtrati (95% Cl) Total et 2023 Jiang et al 2023 Xim et al 2024 Xim et al 2024 Xim et al 2024 Xim et al 2024 Xim et al 20	0 0.38, df = 5 (Z = 1.75 (P = toma 1 1 1 1 1 1 0 0 0 0 0 1 1.30, df = 6 (Z = 0.15 (P = 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1	376 P = 1.0 = 0.08) 23 32 47 35 27 25 30 23 35 27 25 30 23 35 27 25 30 23 35 27 25 30 23 35 27 27 25 30 23 35 27 27 27 28 30 23 35 27 27 27 27 28 30 29 23 35 27 27 27 27 27 27 27 27 27 27	7 7 1 2 1 2 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1	428 0% 46 41 32 55 40 33 24 43 365 18 41 365 0% 46 41 44 25 53 20% 46 41 44 44 25 55 33 28 44 36 54 40 44 40 44 40 44 40 44 40 44 40 33 32 44 40 33 32 44 36 56 56 36 56 56 56 56 56 56 56 56 56 56 56 56 56	10.6% 0.7% 1.9% 1.3% 0.9% 1.5% 1.5% 2.6% 2.6% 1.6% 1.1% 4.4% 1.1% 6.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.37 [0.11, 28.84] 1.15 [0.07, 15.05] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 (0.03, 2.55] 0.39 (0.03, 2.55] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 5.55] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 5.55] 0.45 (0.07, 8.82] Not estimable 0.33 [0.03, 5.55] 1.00 [0.06, 16.82] 0.21 [0.07, 19.59] 1.16 [0.16, 8.86] 0.59 [0.25, 1.37]	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events Heterogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epideral Effect: 1.11.4 Epideral Effect: 1.11.4 Epideral Effect: 1.11.4 Epideral Effect: 1.11.6 ang et al. 2023 Arong et al. 2023 Heterogeneity: Chi ² = Test for overall effect: 1.11.5 Transient neur Heo et al. 2023 Huang et al. 2023 Huang et al. 2023 Arong et al. 2024 Arong et al. 2024	0.38, df = 5 (0.38, df = 5 (Z = 1.75 (P = toma 1 1 2 1 1 0 0 0 0 1 1.30, df = 6 (2 0.51 (P = 2 0 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1	376 P = 1.0 = 0.08) 23 32 47 32 35 309 P = 0.5 = 0.88) ptoms 23 32 23 35 309 P = 0.5 23 32 23 35 36 23 35 36 23 35 36 23 35 36 27 28 35 36 29 29 35 36 20 35 36 20 35 36 20 35 36 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 36 20 20 35 20 20 35 20 20 20 20 20 20 20 20 20 20	7 7)0); ² = 1 1 2 1 1 1 1 1 1 1 1 1 0 0 1 1 0 0 1 1 2 0 0 1 1 2 2 0 0 0 1 2 2 2 0 0 1 2 2 1 2 1	428 0% 46 41 32 55 40 33 32 40 33 33 25 6 0% 46 41 44 42 55 32 25 53 328 24 24 40 4	10.6% 0.7% 1.9% 1.3% 1.5% 1.5% 2.6% 2.6% 1.6% 1.4% 1.6% 1.6% 1.6% 1.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55] 0.39 [0.34, 2.55] 0.39 [0.34, 2.55] 0.30 [0.03, 3.76] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 3.76] 0.33 [0.03, 3.76] 0.33 [0.03, 3.76] 0.24 [0.07, 9.82] Not estimable 1.00 [0.06, 16.82] 0.21 [0.07, 2.20] 1.16 [0.16, 8.86] 0.59 [0.25, 1.37]	
Line et al 2021 Subtotal (95% CI) Total events Heterogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epideral herea Hete et al 2021 Kang et al 2022 Kang et al 2022 Kang et al 2022 Song et al 2022 Yang et al 2023 Zhu et al 2023 Zhu et al 2023 Zhu et al 2023 Subtotal (95% CI) Total events Heterogenetic; Chi ² = Test for overall effect: 1.11.5 Transient neur Hete et al 2021 Song et al 2022 Song et al 2023 Xing et al 2023 Xing et al 2023 Song et al 2023 Song et al 2023 Song et al 2023 Song et al 2022 Song et al 2023 Zhu et al 2023 Song et al 2023 Zhu et al 2023 Song et al 2023 Zhu et al 2023 Zhu et al 2023 Zhu et al 2023 Zhu et al 2023 Song et al 2023 Zhu et al 2023 Zhu et al 2023	$\begin{array}{c} & & & \\ & & & \\ & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 0 & & & \\ 1 & & & \\ 1 & & & \\ 0 & &$	376 P = 1.0 = 0.08) 23 32 47 32 35 30 27 25 30 27 25 30 32 23 35 30 9 P = 0.5 = 0.88) ptoms 23 32 27 27 27 27 23 35 30 27 27 27 27 27 27 27 27 27 27	7 7 7 7 7 7 7 7 7 7 7 7 7 7	428 0% 46 41 325 55 40 33 324 355 55 33 8 41 44 42 55 53 30% 46 41 44 42 55 53 328 41 404 0%	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.6% 1.1% 1.0% 1.9% 16.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.06] 0.38 [0.02, 9.66] 0.39 [0.03, 9.66] 0.39 [0.04, 2.45] 0.22 [0.01, 4.74] Not estimable 1.29 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] 0.21 [0.07, 19.59] Not estimable 1.00 [0.06, 16.82] 0.21 [0.7, 19.59] 1.17 [0.07, 19.59] 1.18 [0.16, 8.86] 0.59 [0.25, 1.37]	
Line et al 2021 Subtrait (95% Cf) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epiderual herma teo et al 2023 Kang et al 2023 Kang et al 2022 Song et al 2022 Song et al 2023 Yu et al 2023 Subtotal (95% CI) Total events Heterogenetic; Chi ² = Test for overall effect: 1.11.5 Transient neur Huang et al 2023 Song et al 2024 Song	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 35 30 27 25 30 23 35 309 P = 0.5 = 0.88) ptoms 23 32 23 33 24 27 27 27 28 23 30 23 30 23 30 23 30 23 30 27 27 28 30 29 20 30 20 30 20 20 30 20 20 30 20 20 30 20 20 20 30 20 20 20 30 20 20 20 30 20 20 20 30 20 20 20 30 20 20 20 30 20 20 20 30 20 20 30 20 30 20 30 20 30 20 30 20 30 20 30 20 30 20 32 20 20 20 20 20 20 20 20 20 2	7 7 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 2 2 0 0 1 2 2 2 0 0 1 1 2 2 2 0 0 1 2 1 2	428 0% 46 41 355 40 324 355 81 41 365 0% 46 41 44 425 53 30% 46 41 44 425 55 33 328 24 35 338 24 41 404 0%	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 2.6% 1.6% 1.1% 4.4% 1.0% 1.9%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.60] 0.38 [0.02, 9.63] 0.39 (0.03, 9.66] 0.39 [0.03, 9.64] 0.39 [0.03, 9.65] 0.39 [0.03, 9.65] 0.22 [0.01, 4.74] Not estimable 1.29 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] 0.02 [0.07, 19.59] 1.17 [0.07, 19.59] 1.18 [0.16, 8.86] 0.59 [0.25, 1.37]	
Line et al 2021 Subtoral (95% CI) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al 2014 teo et al 2021 tim et al 2021 tim et al 2022 Song et al 2023 Yu et al 2022 Song et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Subtoral (95% CI) Total events teo et al 2019 teo et al 2021 tim et al 2023 Subtoral (95% CI) Total events teo et al 2021 Sign et al 2023 Song et al 2023 Song et al 2023 Song et al 2023 Song et al 2023 Zu et al 2023 Song et al 2023 Zu et al 2023 Song et al 2023 Zu et al 2023 Song et al 2023 Zu et al 2021 Song et al 2023 Zu et al 2023 Zu et al 2023 Zu et al 2023 Song et al 2024 Song et al	$\begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $	376 P = 1.0 = 0.08) 23 32 47 32 25 30 23 35 30 23 30 9 P = 0.5 23 32 47 25 30 23 35 30 23 30 9 P = 0.5 23 32 47 32 23 35 27 23 30 23 23 23 23 23 24 25 30 23 23 25 30 23 23 23 23 23 23 23 23 23 23	7 7 7 7 7 7 7 7 7 7 7 7 7 7	428 0% 466 41 32 55 33 24 43 55 18 41 365 0% 46 41 41 425 55 33 28 44 352 55 33 28 44 32 55 33 28 44 30%	0.7% 1.9% 1.9% 1.5% 1.5% 2.6% 2.6% 2.6% 2.6% 1.6% 1.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.07, 9.60] Not estimable 0.38 [0.07, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.24, 255] 0.22 [0.01, 4.74] Not estimable 0.38 [0.03, 8.76] 0.22 [0.01, 4.74] Not estimable 0.38 [0.03, 8.76] 0.22 [0.01, 4.74] Not estimable 0.38 [0.03, 8.76] 0.25 [0.07, 9.82] Not 0.65 [1.62, 1.62] 0.24 [0.07, 9.82] 1.16 [0.16, 8.86] 0.59 [0.25, 1.37]	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events telerogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epidural herma teo et al. 2023 Kong et al. 2023 Kong et al. 2023 Yu et al. 2022 Yu et al. 2023 Yu et al. 2023 Yang et al. 2024 Yang et al. 2024 Yang et al. 2024 Yang et al. 2025 Yang et al. 2024 Yang et al. 2025 Yang et al. 2024 Yang et	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 25 30 9 P = 0.5 = 0.88) ptoms 23 32 25 47 30 23 30 9 P = 0.5 = 0.22) 72	7 7 1 2 1 1 2 1 1 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	428 428 46 41 32 55 40 33 24 33 24 35 18 41 365 0% 46 41 41 42 55 32 28 23 28 23 28 23 20% 46 0% 73 73	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable Not estimable Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55] 0.39 [0.24, 26] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 3.76] 0.38 [0.07, 9.82] Not estimable 1.09 [0.06, 16.82] 0.21 [0.07, 2.02] 1.17 [0.07, 15.59] 1.18 [0.16, 8.86] 0.59 [0.25, 1.37] 0.20 [0.01, 4.18]	
Line et al 2021 Line et al 2021 Line et al 2021 Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural heme teo et al 2019 teo et al 2023 Kang et al 2022 Kang et al 2022 Song et al 2023 Yu et al 2022 Song et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Line events telerogenetic, Chi ² = Test for overall effect: 1.11.5 Transient neur Kang et al 2021 Song et al 2023 Song et al 2023 Xinu et al 2021 Song et al 2023 Xinu et al 2023 Song et al 2023 Xinu et al 2021 Visti Al 2023 Xinu et al 2021 Visti Al 2024 Visti Al 2024 Visti Al 2025 Visti A	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 25 33 32 27 25 30 23 35 57 27 28 28 28 28 28 28 29 20 30 20 23 32 27 27 28 30 20 32 27 27 28 30 20 32 27 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 27 32 32 27 32 27 32 32 27 32 27 32 27 32 32 27 32 27 28 30 27 27 32 27 28 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 27 28 27 27 28 27 27 28 27 27 27 27 27 27 27 27 27 27	7 7 7 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 2 2 2 2	428 0% 466 41 32 55 18 33 24 35 18 33 24 35 0% 466 41 355 18 33 32 4 40 40 0% 73 46	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 1.5% 8.7% 0.9% 2.6% 1.6% 1.1% 4.4% 1.1% 1.8%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 9.06] 0.38 [0.07, 9.05] 0.39 [0.08, 21.46] 0.39 [0.02, 9.06] 0.39 [0.03, 3.76] 0.45 (0.07, 19.59] 0.22 [0.01, 4.74] Not estimable 0.32 [0.07, 19.59] 1.17 [0.07, 19.59] 1.17 [0.07, 19.59] 1.18 [0.16, 8.86] 0.59 [0.25, 1.37] 0.20 [0.01, 4.18] 1.00 [0.09, 11.64]	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events telerogenetic: Chi ² = 1 Test for overall effect: 1.11.4 Epidural herma teo et al. 2023 Arang et al. 2024 Arang et al. 2024 Ara	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 25 30 25 30 25 30 25 30 25 30 25 30 25 30 25 30 25 30 25 30 25 30 25 30 23 25 30 23 25 30 23 25 30 23 25 20 35 27 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 27 28 35 29 20 35 20 35 20 35 27 28 35 27 28 28 28 28 28 28 28 28 28 27 27 28 28 28 28 27 27 28 28 28 28 27 27 28 28 27 27 28 28 27 27 28 28 27 27 28 28 27 27 28 27 22 23 35 32 27 27 28 27 22 32 32 35 32 27 27 22 32 32 32 35 32 28 28 28 28 28 28 28 28 28 2	7 7 1 2 1 1 2 1 1 1 1 0 1 1 0 1 1 0 1 1 0 1 0 1 1 0 1 0 1 1 0 1 1 0 1 1 0 1 2 2 0 0 2 2 0 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2	428 0% 46 41 32 55 40 33 24 35 18 41 365 0% 46 41 44 42 55 33 24 40 40 40 40 40 40 40 40 40 4	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.24, 255] 0.39 [0.24, 255] 0.22 [0.01, 4.74] Not estimable 0.22 [0.01, 4.74] Not estimable 0.22 [0.01, 4.74] Not estimable 0.22 [0.07, 9.82] Not estimable 1.00 [0.06, 16.82] 0.25 [0.25, 1.37] 0.20 [0.01, 4.16] 1.00 [0.09, 11.64] 0.30 [0.03, 2.81]	
Line et al 2021 Subtrat (95% C1) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epiderus heme teo et al 2023 Kang et al 2023 Kang et al 2022 Song et al 2022 Song et al 2022 Song et al 2023 Yu et al 2023 Zu et al 2023 Yu et al 2023 Yu et al 2023 Yu et al 2023 Subtotal (95% C1) Total events Heterogenetic; Chi ² = Test for overall effect: 1.11.5 Transient neur Heterogenetic; Chi ² = Test for 2023 Song et al 2024 Song et al 2024	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 35 27 25 33 35 27 23 35 27 23 36 25 36 27 28 30 29 23 36 27 28 30 29 29 30 29 20 30 29 20 30 20 30 20 20 30 20 30 20 20 30 20 20 30 20 20 30 20 20 20 20 20 20 20 20 20 2	7 7 7 7 1 2 1 1 2 1 1 1 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0 1 0 1 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	428 0% 466 41 32 555 33 24 35 18 365 0% 466 41 44 425 55 33 365 0% 466 41 404 0%	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 1.5% 2.6% 2.6% 2.6% 1.1% 1.0% 1.9% 16.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable 0.38 [0.07, 19.05] 0.38 [0.07, 9.80] 0.38 [0.02, 9.63] 0.39 [0.22, 9.63] 0.34, 2.55] 0.32 [0.01, 4.74] Not estimable 1.09 [0.06, 14.82] 0.22 [0.01, 4.74] Not estimable 1.00 [0.05, 16.82] 0.21 [0.02, 9.63] 1.17 [0.07, 19.59] 1.18 [0.16, 8.86] 0.55 [0.25, 1.37] 0.20 [0.01, 4.16] 1.00 [0.09, 11.64] 0.03 [0.03, 2.81]	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events Heterogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epideral heterol Hete et al. 2023 Arang et al. 2021 Arang et al. 2021 Arang et al. 2023 Arang et al. 2021 Heterogeneity: Chi ² = . Test for overall effect: Arang et al. 2021 Heterogeneity: Chi ² = . Test for overall effect: Arang et al. 2021 Heterogeneity: Chi ² = . Test for overall effect: Arang et al. 2021 Heterogeneity: Chi ² = . Test for overall effect: Arang et al. 2021 Heterogeneity: Chi ² = . Test for overall effect: Arang et al. 2021 Arang et al. 2021 Arang et al. 2021 Arang et al. 2023 Arang et al. 2021 Arang et al. 2023 Arang et al. 2024 Arang et al. 2024 Arang et al. 2024 Arang et al. 2025 Arang et al. 2024 Arang et al. 2024 Arang et al. 2024 A	$\begin{array}{c} & & & & \\ & & & & \\ & & & & \\ & & & & $	376 P = 1.0 = 0.08) 23 32 47 32 25 30 22 33 32 25 30 9 P = 0.5 33 22 33 32 25 30 9 P = 0.5 32 23 32 25 30 23 35 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 28 27 27 27 28 27 27 27 28 27 27 27 28 27 27 27 27 27 27 27 27 27 27	7 7 7 1 2 1 1 1 1 0 1 0 1 1 0 2 2 0 0 2 2 2 0 0 2 2 2 0 0 2 2 2 0 0 2 2 2 2 0 0 2 2 2 2 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2	428 0% 46 41 32 55 40 33 34 41 365 365 0% 46 41 41 365 32 33 28 41 365 33 28 40 41 365 33 28 40 41 365 58 59 58 40 33 28 58 59 58 59 59 59 59 59 59 59 59 59 59	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.4% 3.44% 1.4% 3.1.4% 3.1.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.5, 7.26] 1.38 [0.12, 15.87] 1.74 [0.7, 19.05] Not estimable 0.38 [0.01, 863] 0.38 [0.01, 863] 0.38 [0.03, 2.63] 0.39 [0.34, 2.55] Not estimable 0.38 [0.02, 2.63] 0.34 [0.08, 21.46] 0.22 [0.01, 4.74] Not estimable 0.33 [0.03, 3.76] 0.25 [0.07, 9.82] Not estimable 0.36 [0.02, 2.02] 1.17 [0.07, 16.58] 0.20 [0.01, 4.16] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.00 [0.09, 11.64] 1.01 [0.07, 19.59]	
Line et al 2021 Subtrati (95% CI) Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epiderual herma telerogenetic, Chi ² = 1 teo et al 2023 Kim et al 2023 Via et al 2022 Song et al 2023 Via et al 2023 Vi	$\begin{array}{c} & & & \\$	376 P = 1.0 = 0.08) 23 32 47 32 25 30 27 23 35 5 0 0 0 0 0 23 32 27 27 23 35 0 0 0 0 0 0 0 0 0 0 0 0 0	$\begin{array}{c} & & & \\$	428 0% 46 41 32 55 40 33 42 40 33 41 365 0% 46 41 41 365 55 33 82 24 40 365 0% 73 46 41 40 41 55 55 40 33 41 55 55 40 33 41 41 41 41 41 41 41 41 41 41	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 2.6% 2.6% 2.6% 1.6% 1.1% 4.4% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] 1.15 [0.07, 19.05] Not estimable Not estimable 0.38 [0.07, 19.05] 0.38 [0.07, 9.82] 0.38 [0.07, 9.82] Not estimable 0.22 [0.01, 4.74] Not estimable 0.22 [0.01, 4.74] Not estimable 0.02 [0.00, 2.146] 0.33 [0.03, 3.76] 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] 0.21 [0.07, 9.82] 1.18 [0.16, 8.86] 0.59 [0.25, 1.37] 0.20 [0.01, 4.18] 1.00 (0.9, 11.64] 0.30 [0.03, 2.81] Not estimable 1.17 [0.07, 19.59] 1.17 [0.7, 19	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema teo et al. 2012 Kinn et al. 2023 Kinn et al. 2021 Kinn et al. 2022 Song et al. 2023 Yu et al. 2023 Link et al. 2023 Link et al. 2023 Link et al. 2023 Link et al. 2023 Kinn et al. 2023 Kinn et al. 2023 Kinn et al. 2023 Link et al. 2023 Link et al. 2023 Kinn et al. 2023 Xinn et al. 2021 Heierogenetic, Chi ² = 1 Sets for overall effect: 1.11.6 Cage subsider Statum et al. 2021 Yang et al. 2023 Xinn et al. 2021 Yang et al. 2023 Xinn et al. 2021 Yang et al. 2023 Xinn et al. 2023	$\begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $	376 P = 1.0 = 0.08) 23 32 47 32 25 30 22 33 22 23 35 30 9 P = 0.5 23 32 25 30 9 P = 0.5 23 32 24 35 27 27 23 30 23 32 25 30 23 35 27 27 30 27 27 30 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 30 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 37 27 27 37 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 37 27 27 27 27 27 27 27 27 27 2	7 7 00); ² = 1 2 1 1 1 1 1 1 0 0 0 1 1 2 2 2 0 0 1 1 2 2 0 0 1 2 2 2 0 1 1 2 2 2 2 4 4 0 0 1 1 2 2 2 4 1 0 0 1 2 2 2 2 2 4 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	428 0% 46 41 32 55 40 33 42 40 33 42 40 365 58 33 28 40 365 58 33 28 40 30% 46 41 41 41 41 41 41 41 41 41 41	10.6% 0.7% 1.9% 1.5% 1.5% 2.6% 2.6% 2.6% 1.6% 1.6% 1.6% 1.6% 1.1% 1.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.34] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] 0.22 [0.01, 4.74] 0.25 [0.07, 9.82] Not estimable 1.00 [0.06, 16.82] 0.21 [0.07, 18.59] 0.25 [0.07, 9.82] Not estimable 0.35 [0.07, 9.82] Not estimable 1.00 [0.09, 11.64] 0.39 [0.03, 9.1164] 0.30 [0.03, 9.1164] 0.30 [0.03, 9.1164] 0.30 [0.03, 2.61] Not estimable 1.17 [0.07, 19.59] 1.62 [0.14, 19.41] Not estimable 1.17 [0.07, 19.59] 1.62 [0.14, 19.41] Not estimable	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events telerogenetic: Chi ² = 1 Test for overall effect: 1.11.4 Epidural hema telero et al. 2023 Arang et al. 2021 Arang et al. 2021 Arang et al. 2022 Vi et al. 2022 Vi et al. 2022 Vi et al. 2022 Vi et al. 2023 Tru et al. 2023 Arang et al. 2021 Subtotal. (95% CI) Total events teletorogenety: Chi ² = 1 Test for overall effect: 1.11.6 Cage subsider 3.2023 Arang et al. 2021 Arang et al. 2023 Arang et al. 2024 Arang et al. 2023 Arang et al. 2024 Arang et al.	$\begin{array}{c} 3.36 \text{ df} = 5 (\\ 3.38 \text{ df} = 5 (\\ 7 = 1.75 (P = 1.75 (P$	376 P = 1.0 23 32 47 25 30 27 25 30 27 25 30 27 25 30 9 P = 0.5 30 9 P = 0.5 23 32 35 30 9 P = 0.5 23 32 35 27 25 27 25 30 35 27 25 20 27 25 30 27 25 27 25 30 35 27 25 27 25 30 35 23 35 23 35 23 35 23 35 23 35 27 25 27 25 27 25 20 35 27 25 27 25 20 27 25 20 35 23 35 23 35 23 25 27 25 27 25 20 35 23 35 23 25 27 25 27 25 27 25 27 25 27 25 23 35 23 35 27 27 27 27 28 36 27 27 27 28 36 27 27 27 27 28 36 27 27 27 28 36 27 27 27 27 28 36 27 27 27 27 27 28 36 27 27 27 27 28 36 27 27 27 27 28 36 27 27 27 27 27 27 28 36 36 27 27 27 27 27 28 36 37 27 27 27 27 27 27 27 27 27 2	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$	428 0% 46 41 32 55 40 33 34 41 35 55 33 365 0% 46 41 41 44 25 55 33 28 24 35 365 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 2.6% 1.6% 1.6% 1.6% 2.8% 1.6% 1.5% 1.1% 10.1%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.5, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.24, 2.55] 0.39 [0.24, 2.55] 0.30 [0.03, 2.63] Not estimable 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] 0.22 [0.07, 9.82] Not estimable 1.00 [0.06, 16.86] 0.59 [0.25, 1.37] 0.20 [0.01, 4.16] 1.00 [0.09, 1.14] 1.00 [0.09, 1.14] 0.30 [0.03, 2.81] Not estimable	
Link et al. 2021 Link et al. 2021 Link et al. 2021 Total events telerogeneity: Chi ² = 1 Test for overall effect: 1.11.4 Epidural herma teo et al 2023 Kong et al 2022 Vin et al 2022 Vin et al 2022 Vin et al 2023 Vin et al 2024 Vin et al 20	$\begin{array}{c} 3.38, dff = 5 \\ 0.38, dff = 5 \\ Z = 1.75 (P = 1) \\ 1 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	376 P = 1.0 23 32 47 25 32 32 27 25 30 27 25 30 23 35 36 27 25 30 9 P = 0.5 23 32 27 27 25 30 9 P = 0.88) ptoms 23 32 27 27 28 30 29 20 35 20 20 35 20 20 20 35 20 20 20 20 35 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} & & & \\$	428 0% 46 41 32 55 40 33 34 41 355 0% 46 41 41 365 0% 46 41 41 365 0% 73 365 55 33 24 365 0% 0% 73 73 68 24 25 55 55 55 75 76 76 76 76 76 76 76 76 76 76	10.6% 0.7% 1.9% 0.8% 1.0% 1.5% 8.7% 0.9% 2.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.84] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.28, 63] 0.39 [0.28, 63] 0.39 [0.28, 128] 0.22 [0.01, 4.74] Not estimable 0.22 [0.01, 4.74] Not estimable 0.21 [0.06, 15.82] Not estimable 1.00 [0.06, 16.82] 0.25 [0.25, 1.37] 0.20 [0.01, 4.18] 1.00 [0.09, 11.64] 0.30 [0.03, 2.81] Not estimable 0.30 [0.03, 2.81] Not estimable 0.30 [0.03, 2.81] Not estimable 1.17 [0.07, 19.59] 1.62 [0.14, 19.41] 0.61 [0.21, 1.76]	
Line et al 2021 Subtrati (95% CI) Total events Telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epiderus heme telerogenetic, Chi ² = 1 Test for overall effect: 1.11.4 Epiderus heme teo et al 2023 Kim et al 2021 Via et al 2022 Song et al 2022 Via et al 2023 True et al 2023 Via	$\begin{array}{c} & & & \\$	$\begin{array}{r} 376 \\ P = 1.0 \\ c = 0.08 \\ 322 \\ 47 \\ 32 \\ 32 \\ 32 \\ 32 \\ 33 \\ 32 \\ 33 \\ 33 \\ 30 \\ 9 \\ 23 \\ 30 \\ 9 \\ 23 \\ 30 \\ 9 \\ 23 \\ 32 \\ 32 \\ 32 \\ 32 \\ 32 \\ 32 $	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\$	428 0% 46 41 325 55 18 40 365 0% 46 41 41 365 0% 46 41 41 365 33 24 33 24 33 24 33 24 36 33 24 40 365 18 26 53 26 40 32 26 55 18 26 26 26 26 26 26 26 26 26 26	10.6% 0.7% 1.9% 1.5% 1.5% 2.6% 2.6% 1.6% 1.4% 1.6% 1.4% 1.6.1% 2.8% 1.0% 1.0% 10.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.11, 28.84] 1.15 [0.07, 19.05] Not estimable Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.39 [0.34, 2.55] 0.39 [0.06, 1.46] 0.22 [0.01, 4.74] Not estimable 1.29 [0.06, 16.80] 0.22 [0.01, 4.74] Not estimable 1.00 [0.06, 16.82] 0.21 [0.07, 9.59] 1.16 [0.16, 8.86] 1.29 [0.25, 1.37] 0.20 [0.01, 4.18] 1.00 [0.09, 11.64] 0.30 [0.03, 2.81] Not estimable 1.17 [0.07, 19.59] 1.20 [0.07, 14.18] 1.00 [0.09, 11.64] 1.21 [0.07, 19.59] 1.22 [0.14, 13.41] 0.64 [0.21, 1.76] 0.71 [0.51, 0.971]	
Linu et al 2021 Subtotal (95% CL) Total events Heterogenetix Chi ² = 1 Fest for overall effect: 1.11.4 Epidural hema teo et al 2023 fang et al 2021 fang et al 2021 fang et al 2023 fang et al 2024 fang et al 2022 fang et al 2023 fang et al 2022 fang et al 2023 fang et al 2024 fang et al 2023 fang et al 2023 fang et al 2024 fang et al 2025 fang et al 2024 fang et al 2024 fa	$\begin{array}{c} & & & & \\ & & & & \\ & & & & \\ & & & & $	376 P = 1.0 23 32 23 32 23 32 25 30 22 33 27 25 30 22 33 27 25 30 23 35 30 23 35 30 23 35 23 35 27 23 36 23 36 27 23 36 27 23 36 27 23 36 27 23 36 27 23 36 23 36 27 23 36 27 27 28 38 27 28 28 28 27 27 28 28 28 27 27 28 28 27 27 28 28 27 27 28 28 27 27 28 28 27 27 28 27 27 27 28 28 27 27 28 27 27 28 28 27 27 27 28 28 27 27 27 28 27 27 27 28 27 27 27 28 27 27 27 28 27 27 27 27 28 27 27 27 28 27 27 27 27 27 27 27 28 27 27 27 27 27 27 27 27 27 27	$\begin{array}{c} & & & \\$	428 0% 46 41 33 24 33 24 33 24 33 24 365 0% 46 41 41 365 0% 46 41 40 40 0% 73 36 55 55 33 24 40 33 24 40 36 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 18 41 365 55 55 18 41 365 55 55 18 41 365 55 55 55 18 41 365 55 55 55 55 55 55 55 55 55	10.6% 0.7% 1.9% 1.5% 1.5% 2.6% 2.6% 2.6% 1.6% 1.6% 1.6% 1.6% 1.1% 10.0% 10.0%	0.31 [0.08, 1.15] 2.05 [0.12, 34.26] 0.63 [0.05, 7.26] 1.38 [0.12, 15.87] 1.74 [0.17, 128.34] Not estimable 0.38 [0.01, 9.60] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] Not estimable 0.38 [0.02, 9.63] 0.34, 2.55] 0.22 [0.01, 4.74] 0.22 [0.01, 4.74] 0.25 [0.07, 9.82] 0.45 [0.07, 9.82] 0.45 [0.07, 9.82] 0.45 [0.07, 9.82] 0.45 [0.07, 9.82] 0.45 [0.07, 9.82] 1.16 [0.16, 8.86] 0.39 [0.03, 1.16] 0.30 [0.03, 1.16] Not estimable 0.30 [0.03, 2.11] Not estimable 1.00 [0.09, 11.64] 0.30 [0.03, 2.81] Not estimable 0.30 [0.03, 2.81] Not estimable 0.45 [0.21, 1.76]	

Fig. 13 Forest plot of the number of complications

remained consistent with the original conclusions, suggesting that heterogeneity had minimal influence on the study outcomes. Factors contributing to heterogeneity may include differences in surgeon experience, operating techniques, methods for measuring intraoperative blood loss, and completeness and accuracy of case records.

Publication deviation

The study included 14 articles and tested all outcome measures for publication bias. The funnel plot was visually assessed for each outcome measure, and it appeared to be mostly symmetrical, indicating a low likelihood of publication bias. Figures 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 provide supporting evidence for this finding.

Discussion

With the rapid development of the concept, tools, and techniques of minimally invasive spinal surgery, how to make lumbar fusion surgery achieve the effect of decompression and fusion while minimizing trauma has become the goal pursued by spinal surgeons. MIS-TLIF employs tubular retractors and cold light source systems to selectively remove portions of the facet and lamina on the surgical side. By accessing the intervertebral disk through the transforaminal approach, it achieves nerve decompression and interbody fusion. Since its introduction to clinical practice, both orthopedic surgeons and patients have acknowledged MIS-TLIF for its precision and minimal invasiveness [25]. However, it still has the following disadvantages: (1) tubular retractors can also cause a certain degree of surgical trauma to the skin and muscle traction, which is easy to cause postoperative skin and muscle necrosis and long-term scar healing [26]; (2) the field of view using an air medium tends to blur easily, and the lighting in deeper channels and corners remains dim. This limitation becomes especially pronounced during contralateral undermining decompression; (3) endplate treatment depends on hand feeling, it is difficult to observe directly, and it is easy to have insufficient cartilage endplate treatment or damage the bony endplate [19].

The BE-TLIF technique is a new endoscopic technique that applies the traditional arthroscopic system to the spine, establishes an operating channel and an observation channel through a small incision, does not require an auxiliary tube to expose the field of view when completing spinal canal decompression and cage placement, has a large operating space, and is more flexible in the use of the device [5, 27]. BE-TLIF combines microscopic and endoscopic features and has the following advantages: (1) It has independent observation channels and working channels. By observing the channel perfusion arthroscope, the surgeon can directly look at the surgical field and clearly distinguish the structures around the nerve tissue; the working channel can be flexibly operated using conventional instruments for spinal surgery,



Fig. 14 Funnel plot of publication bias for operation time





with high work efficiency and easy popularization [3]. (2) Dissection of the paravertebral musculature rarely and maximally preserves the integrity of the spinal structure

and maintains postoperative spinal stability; dissection of the paravertebral muscle close to the posterior laminar structure establishes a practical working space and is



Fig. 17 Funnel plot of publication bias for back VAS



Fig. 18 Funnel plot of publication bias for leg VAS



Fig. 19 Funnel plot of publication bias for ODI



Fig. 20 Funnel plot of publication bias for LL



Fig. 21 Funnel plot of publication bias for DH

a familiar anatomy for the surgeon. (3) The procedure is conducted under continuous irrigation. Instead of a conventional electrotome, a radiofrequency electrode is used for hemostasis. This allows for effective cauterization of microvascular bleeding around the dural sac without causing nerve damage. Additionally, the absence of surgical smoke minimizes wound contamination, which can significantly reduce the risk of surgical site infections [8]. (4) UBE is not limited by a rigid conduit, the inner wall of the ipsilateral pedicle can be detected in the extent of decompression, and the contralateral side can reach the lateral recess by removing part of the spinous process root crossing the midline, and the dural sac, bilateral nerve root courses, and contralateral outlet root can be completely exposed after decompression to achieve fine exploration, release, and decompression of the nerve in the target area of the spinal canal under direct vision [15]. (5) The cartilage endplate can be completely removed and the bone graft bed can be prepared by magnifying the visual field under the microscope, which lays a good environment for bone graft fusion [3, 11].

The results of this study showed that the VAS score and ODI of low back pain and leg pain in the BE-TLIF group were lower than those in the MIS-TLIF group at the early postoperative follow-up, and the differences were statistically significant. The results showed that BE-TLIF could reduce the lumbar pain and improve the functional recovery of patients in the early stage. Because UBE was operated endoscopically throughout the operation, it had the advantages of both visual field magnification and flexible operation, which could protect the normal anatomy of the spine as much as possible and facilitate the early postoperative recovery [28]. This is consistent with Huang et al. [10] who also found that VAS score for lumbago and leg pain and ODI recovery in the early postoperative period were significantly better in the BE-TLIF group than in the MIS-TLIF group, and the length of hospital length stay was shorter, but there was no significant difference between groups at the final followup. Our findings indicate that the postoperative hospital length stay for the BE-TLIF group was shorter than that of the MIS-TLIF group, with the difference being statistically significant. This may be attributed to the more rapid alleviation of lumbar pain symptoms in patients who underwent BE-TLIF. As a result, these patients met discharge criteria sooner and were able to return to their normal lives more quickly.

In addition, compared with the MT-TLIF group, the BE-TLIF group had less intraoperative blood loss and postoperative drainage volume, and the reasons for less blood loss may be: (1) BE-TLIF requires normal saline irrigation fluid perfusion during surgical decompression and interbody bone grafting, has a certain water pressure, and plays a role in compression hemostasis; (2)





BE-TLIF magnifies the surgical field through the imaging system, allowing for clear visualization of minor blood vessel bleeding on the monitor. By using a radiofrequency electrode for hemostasis, it achieves an effective bleeding control result [3]. However, the operation time was longer and the analysis may be related to the steep learning curve of this technique [29, 30]. Choi et al. [31] examined the learning curve of 68 UBE procedures conducted by a surgeon with 8 years of spinal surgery experience. They observed that the learning curve for UBE procedures began to stabilize after 36 cases. They emphasized that the clarity of the intraoperative visual field and effective bleeding control were crucial factors influencing the duration of the operation. A compromised





Fig. 24 Funnel plot of publication bias for complications

intraoperative clarity could extend the time required to establish the workspace and identify surgical landmarks. Consequently, we advise spine surgeons to become proficient with the UBE technique and reach a stable point in the learning curve before undertaking the BE-TLIF procedure. This ensures that patients aren't negatively impacted by prolonged surgical durations.

In our study, there was no notable difference in the lumbar interbody fusion rate at the final follow-up between the two groups. This suggests that both BE-TLIF and MIS-TLIF procedures result in satisfactory fusion rates. While endplate bleeding serves as a reliable indicator, the preparation of the endplate remains crucial for successful interbody fusion [5, 32]. Because of the limited working space, bone bleeding can hardly be observed in procedures such as conventional MIS-TLIF. Surgeons generally estimate the completeness of preparation based on previous experience with the intervertebral space management; while BE-TLIF surgeons are able to directly observe the intervertebral space and remove the remaining annulus fibrosus and nucleus pulposus under direct vision [27]. LL and DH were significantly improved at the last follow-up in both groups compared with those before surgery, but there was no significant difference between the two groups, indicating that both BE-TLIF and MIS-TLIF could improve postoperative intervertebral stability and help to restore the normal sequence of the lumbar spine.

Common complications of BE-TLIF include dural tear, spinal epidural hematoma, inadequate decompression, iatrogenic instability, nerve root injury, infection, and postoperative numbness. Dural tears are a common complication of lumbar degenerative disease surgery, and studies have reported that the incidence of dural tears in lumbar degenerative disease surgery using BE-TLIF ranged from 2.9% to 5.8% [33]. Dural tear was considered to be due to severe stenosis of the spinal canal, and when bilateral decompression was performed by a unilateral approach, dural rupture was caused during dissection due to severe adhesion between the ligamentum flavum and the dura mater [34-36]. Kim et al. [37] concluded that even if dural tears occur, no management is needed because BE-TLIF is less damaging to the low back muscles and protects low back muscle function, so when dural tears occur, the low back muscles can play a role in preventing continuous leakage of cerebrospinal fluid. Spinal epidural hematoma after BE-TLIF is a rare complication among many complications after surgery, but due to its rapid progression, if not timely and effective treatment will cause devastating damage to spinal cord function. In terms of cage subsidence, it may be due to intraoperative destruction of the endplates. Therefore, when cleaning the endplate with more severe degeneration, do not be too violent to avoid damaging the endplate; secondly, when placing the interbody fusion cage, it should enter along the inclination angle of intervertebral space to prevent the interbody fusion cage from destroying the endplate, resulting in postoperative interbody fusion cage subsidence [18]. Complications such as nerve root injury, infection, and postoperative numbness are rarely reported. However, in this study, there was no significant difference in the overall complications and the incidence rate of the above complications between the two groups, and both were improved after symptomatic treatment.

The limitation of this study is that the included literatures are retrospective studies, there is no prospective study for reference, and there is a lack of long-term follow-up to comprehensively evaluate the safety and effectiveness of this technique. In addition, inconsistent follow-up times lead to differences in complications and fusion rates at the final follow-up. Therefore, subsequent prospective studies with large samples and multiple centers are needed to obtain higher levels of evidence support.

Conclusion

In summary, BE-TLIF has the advantages of less intraoperative blood loss and postoperative drainage volume, rapid postoperative recovery, and effective protection of spinal soft tissues, and can achieve similar fusion rates and clinical effects as MIS-TLIF. Although the operation time is relatively long and has a relatively steep learning curve, it can be shortened by a certain accumulation of surgical volume. It provides a new option for minimally invasive treatment of lumbar degenerative diseases.

Acknowledgements

Not applicable.

Author contributions

HPL, KL, CP, and XHS developed the research questions and scope of the study. HPL and CP conducted preoperative and postoperative data screening, and data charting. HPL drafted the manuscript, prepared tables, and figure with KL's contribution. HPL, CP, and XHS developed the literature search strategies in collaboration with the other authors. HPL, KL, and XHS contributed to the organization, analysis, and interpretation of the results. All authors read and approved the final manuscript.

Funding

The study was funded by the National Natural Science Foundation of China (82172454).

Availability of data and material

The data sets generated and analyzed during the current study are not publicly available but can be obtained from the corresponding author on reasonable request.

Declarations

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Spine Surgery, The Six Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. ²Department of Trauma and Microreconstructive Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

Received: 24 August 2023 Accepted: 18 November 2023 Published online: 22 November 2023

References

- 1. Goldstein CL, Phillips FM, Rampersaud YR. Comparative effectiveness and economic evaluations of open versus minimally invasive posterior or transforaminal lumbar interbody fusion. Spine. 2016;41(Suppl 8):1.
- 2. Chen L, Zhu B, Zhong H, Wang Y, Sun Y, Wang Q, Liu J, Tian D, Jing J. The Learning curve of unilateral biportal endoscopic (UBE) spinal surgery by CUSUM analysis. Front Surg. 2022;9: 873691.
- Kim JE, Yoo HS, Choi DJ, Park EJ, Jee SM. Comparison of minimal invasive versus biportal endoscopic transforaminal lumbar interbody fusion for single-level lumbar disease. Clin Spine Surg. 2021;34(2):E64–71.
- Eun SS, Eum JH, Lee SH, Sabal LA. Biportal endoscopic lumbar decompression for lumbar disk herniation and spinal canal stenosis: a technical note. J Neurol Surg Part A. 2017;78(4):390–6.
- Heo DH, Son SK, Eum JH, Park CK. Fully endoscopic lumbar interbody fusion using a percutaneous unilateral biportal endoscopic technique: technical note and preliminary clinical results. Neurosurg Focus. 2017;43(2):E8.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.
- Phan K, Mobbs RJ. Systematic reviews and meta-analyses in spine surgery, neurosurgery and orthopedics: guidelines for the surgeon scientist. J Spine Surg. 2015;1(1):19–27.
- Kang MS, You KH, Choi JY, Heo DH, Chung HJ, Park HJ. Minimally invasive transforaminal lumbar interbody fusion using the biportal endoscopic techniques versus microscopic tubular technique. Spine J. 2021;21(12):2066–77.
- Song X, Ren Z, Cao S, Zhou W, Hao Y. Clinical efficacy of bilateral decompression using biportal endoscopic versus minimally invasive transforaminal lumbar interbody fusion for the treatment of lumbar degenerative diseases. World Neurosurg. 2023;173:e371–7.
- Huang X, Wang W, Chen G, Guan X, Zhou Y, Tang Y. Comparison of surgical invasiveness, hidden blood loss, and clinical outcome between unilateral biportal endoscopic and minimally invasive transforaminal lumbar interbody fusion for lumbar degenerative disease: a retrospective cohort study. BMC Musculoskel Dis. 2023;24(1):274.
- Kong F, Zhou Q, Qiao Y, Wang W, Zhang C, Pan Q, Zhu H. Comparison of unilateral biportal endoscopic transforaminal lumbar interbody fusion versus minimally invasive tubular transforaminal lumbar interbody fusion for lumbar degenerative disease. Chin J Reparative Reconstr Surg. 2022;36(05):592–9.
- Song X, Hao Y, Ren Z, Yu L, Zhu G, Zhou W. Preliminary study of unilateral biportal endoscopic lumbar interbody fusion for the treatment of Gradel-Lumbar spondylolisthesis. Chin J Min Inv Surg. 2022;22(10):814–9.
- Yang K, Peng S, Chang L, Shen X. Comparison of unilateral biportal endoscopic transforaminal lumbar interbody fusion and minimally invasive transforaminal lumbar interbody fusion in the treatment of single-level lumbar degenerative diseases. Shandong Med J. 2023;63(08):71–4.
- Zhu J, Hao Y, Ren Z, Zhu G, Yu L, Zhang P, Cao S, Song X. Preliminary study of unilateral biportal endoscopic lumbar interbody fusion for the treatment of degenerative spinal disease. Chin J Spine Spinal Cord. 2021;31(11):1026–33.
- Heo DH, Park CK. Clinical results of percutaneous biportal endoscopic lumbar interbody fusion with application of enhanced recovery after surgery. Neurosurg Focus. 2019;46(4):E18.

- Gatam AR, Gatam L, Mahadhipta H, Ajiantoro A, Luthfi O, Aprilya D. Unilateral biportal endoscopic lumbar interbody fusion: a technical note and an outcome comparison with the conventional minimally invasive fusion. Orthop Res Rev. 2021;13:229–39.
- Heo DH, Jang JW, Park CK. Enhanced recovery after surgery pathway with modified biportal endoscopic transforaminal lumbar interbody fusion using a large cage. Comparative study with minimally invasive microscopic transforaminal lumbar interbody fusion. Eur Spine J. 2023;1:1–10.
- Yu Y, Wang Y, Xie Y, Xu J, Chen Y, Fan X. Comparison of mid-term effectiveness of unilateral biportal endoscopy-transforaminal lumbar interbody fusion with minimally invasive surgery-transforaminal lumbar interbody fusion assisted with three-dimensional microscope in treating lumbar spondylolisthesis. Chin J Reparat Reconstr Surg. 2023;37(01):52–8.
- Jiang C, Huang Y, Zuo H, Sun Y, Sun J. Clinical effect of unilateral biportal endoscopic lumbar interbody fusion and minimally invasive transforaminal lumbar interbody fusion on single-segment lumbar stenosis with instability. Acta Academiae Medicinae Sinicae. 2022;44(4):563–9.
- Ni S, Zhang Y, Sun H, Chen Y, Hu W, Hao D. Comparison of the clinical outcomes of unilateral biportal endoscopic assisted posterior lumbar interbody fusion with minimally invasive transforaminal lumbar interbody fusion in treating lumbar degenerative diseases. Chin J Spine Spinal Cord. 2022;32(09):805–13.
- Bridwell KH, Lenke LG, McEnery KW, Baldus C, Blanke K. Anterior fresh frozen structural allografts in the thoracic and lumbar spine: Do they work if combined with posterior fusion and instrumentation in adult patients with kyphosis or anterior column defects? Spine. 1995;20(12):1410–8.
- Suk SI, Lee CK, Kim WJ, Lee JH, Cho KJ, Kim HG. Adding posterior lumbar interbody fusion to pedicle screw fixation and posterolateral fusion after decompression in spondylolytic spondylolisthesis. Spine. 1997;22(2):210–9.
- Eck KR, Lenke LG, Bridwell KH, Gilula LA, Lashgari CJ, Riew KD. Radiographic assessment of anterior titanium mesh cages. J Spinal Disord. 2000;13(6):501–9.
- Brantigan JW, Steffee AD. A carbon fiber implant to aid interbody lumbar fusion. Two-year clinical results in the first 26 patients. Spine. 1993;18(14):2106–7.
- Lener S, Wipplinger C, Hernandez RN, Hussain I, Kirnaz S, Navarro-Ramirez R, Schmidt FA, Kim E, Hartl R. Defining the MIS-TLIF: a systematic review of techniques and technologies used by surgeons worldwide. GLOB SPINE J. 2020;10(2 Suppl):151S-167S.
- Foley KT, Holly LT, Schwender JD. Minimally invasive lumbar fusion. Spine. 2003;28(15 Suppl):S26–35.
- Park MK, Park SA, Son SK, Park WW, Choi SH. Clinical and radiological outcomes of unilateral biportal endoscopic lumbar interbody fusion (ULIF) compared with conventional posterior lumbar interbody fusion (PLIF): 1-year follow-up. Neurosurg Rev. 2019;42(3):753–61.
- Chang H, Xu J, Yang D, Sun J, Gao X, Ding W. Comparison of full-endoscopic foraminoplasty and lumbar discectomy (FEFLD), unilateral biportal endoscopic (UBE) discectomy, and microdiscectomy (MD) for symptomatic lumbar disc herniation. Eur Spine J. 2023;32(2):542–54.
- Kim JE, Yoo HS, Choi DJ, Hwang JH, Park EJ, Chung S. Learning curve and clinical outcome of biportal endoscopic-assisted lumbar interbody fusion. Biomed Res Int. 2020;2020:8815432.
- Park SM, Kim HJ, Kim GU, Choi MH, Chang BS, Lee CK, Yeom JS. Learning curve for lumbar decompressive laminectomy in biportal endoscopic spinal surgery using the cumulative summation test for learning curve. World Neurosurg. 2019;122:e1007–13.
- Choi DJ, Choi CM, Jung JT, Lee SJ, Kim YS. Learning curve associated with complications in biportal endoscopic spinal surgery: challenges and strategies. Asian Spine J. 2016;10(4):624–9.
- Ramirez LJ, Ardila AS, Rugeles OJ, Martinez CR, Alonso CG, Infante J, Lewandrowski KU. Standalone lordotic endoscopic wedge lumbar interbody fusion (LEW-LIF) with a threaded cylindrical peek cage: report of two cases. J Spine Surg. 2020;6(Suppl 1):S275–84.
- Lin GX, Huang P, Kotheeranurak V, Park CW, Heo DH, Park CK, Park JY, Kim JS. A systematic review of unilateral biportal endoscopic spinal surgery: preliminary clinical results and complications. World Neurosurg. 2019;125:425–32.
- Kim JE, Choi DJ, Kim MC, Park EJ. Risk factors of postoperative spinal epidural hematoma after biportal endoscopic spinal surgery. World Neurosurg. 2019;129:e324–9.

- Neurosurg. 2019;126:e786–92.
 Zhao XB, Ma HJ, Geng B, Zhou HG, Xia YY. Percutaneous endoscopic unilateral laminotomy and bilateral decompression for lumbar spinal stenosis. Orthop Surg. 2021;13(2):641–50.
- Kim W, Kim SK, Kang SS, Park HJ, Han S, Lee SC. Pooled analysis of unsuccessful percutaneous biportal endoscopic surgery outcomes from a multi-institutional retrospective cohort of 797 cases. Acta Neurochir. 2020;162(2):279–87.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

